Document:

Term Loan and Security Agreement

 Exhibit 10.1 
 TERM LOAN AND SECURITY AGREEMENT 
 LV ADMINISTRATIVE SERVICES,
INC., 
 as Administrative and Collateral Agent 

THE LENDERS 

From Time to Time Party Hereto 
 and 
 BIOVEST INTERNATIONAL, INC. 

Dated:  November 17, 2010 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	1.	  	 General Definitions and Terms; Rules of Construction
	  	 	2	  
	2.	  	 The BVTI Term Loans and Closing Shares
	  	 	2	  
	3.	  	 Repayment of the BVTI Term Loans
	  	 	4	  
	4.	  	 Reserved
	  	 	4	  
	5.	  	 Interest and Payments
	  	 	4	  
	6.	  	 Security Interest
	  	 	5	  
	7.	  	 Representations, Warranties and Covenants Concerning the Collateral
	  	 	7	  
	8.	  	 Payment of Accounts
	  	 	9	  
	9.	  	 Reserved
	  	 	9	  
	10.	  	 Inspections and Appraisals
	  	 	9	  
	11.	  	 Financial Reporting
	  	 	10	  
	12.	  	 Additional Representations and Warranties
	  	 	10	  
	13.	  	 Covenants
	  	 	14	  
	14.	  	 Closing and Conditions to Closing
	  	 	18	  
	15.	  	 Further Assurances
	  	 	22	  
	16.	  	 Representations, Warranties and Covenants of Lenders
	  	 	22	  
	17.	  	 Confidentiality
	  	 	24	  
	18.	  	 Power of Attorney
	  	 	25	  
	19.	  	 Termination of Lien
	  	 	25	  
	20.	  	 Events of Default
	  	 	26	  
	21.	  	 Remedies
	  	 	26	  
	22.	  	 Waivers
	  	 	27	  
	23.	  	 Expenses
	  	 	27	  
	24.	  	 Assignment; Register
	  	 	28	  
	25.	  	 No Waiver; Cumulative Remedies
	  	 	29	  
	26.	  	 Application of Payments
	  	 	29	  
	27.	  	 Indemnity
	  	 	29	  
	28.	  	 Revival
	  	 	30	  
	29.	  	 Borrowing Agency Provisions
	  	 	30	  
	30.	  	 Notices
	  	 	30	  
	31.	  	 Governing Law, Jurisdiction and Waiver of Jury Trial
	  	 	31	  
	32.	  	 Limitation of Liability
	  	 	32	  
	33.	  	 Entire Understanding; Maximum Interest
	  	 	33	  
	34.	  	 Severability
	  	 	33	  
	35.	  	 Survival
	  	 	33	  
	36.	  	 Captions
	  	 	33	  
	37.	  	 Counterparts; Signatures
	  	 	33	  
	38.	  	 Construction
	  	 	33	  

  
 i 

							
	39.	  	 Publicity
	  	 	34	  
	40.	  	 Joinder
	  	 	34	  
	41.	  	 Legends
	  	 	34	  
	42.	  	 Agency
	  	 	35	  

 TERM LOAN AND SECURITY AGREEMENT 

This TERM LOAN AND SECURITY AGREEMENT is made as of November 17, 2010 (as amended, restated, supplemented and/or
modified from time to time, this “Agreement”), by and among the lenders from time to time party hereto (the “Lenders”), LV ADMINISTRATIVE SERVICES, INC., a Delaware corporation, as administrative and collateral
agent for the Lenders (in such capacity, the “Agent” and together with the Lenders, the “Creditor Parties”) and BIOVEST INTERNATIONAL, INC., a Delaware corporation (“Biovest”). 

BACKGROUND 
 WHEREAS, on November 10, 2008 (the “Petition Date”), each of Biovest, Biovax, Inc., AutovaxID, Inc., Biolender, LLC and Biolender II, LLC commenced a voluntary case for
reorganization under Chapter 11 of Title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Bankruptcy Code”), in the United States Bankruptcy Court for the Middle District of Florida, Tampa Division (the
“Bankruptcy Court”), which cases are currently being jointly administered under Case No. 8:08-bk-17795-KRM (the “Bankruptcy Cases”); 

WHEREAS, Biovest and Biovax, Inc., AutovaxID, Inc., Biolender, LLC and Biolender II, LLC have been substantively
consolidated pursuant to the terms of the Confirmed Plan; 
 WHEREAS, as of the Petition Date, Biovest was
indebted to Laurus Master Fund, Ltd. (In Liquidation), Valens U.S. SPV I, LLC, Valens Offshore SPV I, Ltd. and Valens Offshore SPV II, Corp. (collectively, the “Prepetition Lenders”) in an aggregate principal amount of
$30,154,082.65, plus interest and other amounts due thereon, according to proofs of claim filed by the Prepetition Lenders in the Biovest Bankruptcy Cases (the “Prepetition Debt”); 

WHEREAS, in connection with Biovest incurring the Prepetition Debt, Biovest and Accentia issued to certain of the
Prepetition Lenders warrants (the “Biovest Warrants”) to acquire shares of the Biovest Common Stock as listed on Exhibit A attached hereto; 

WHEREAS, in connection with Biovest incurring the Prepetition Debt, Biovest and Accentia, pursuant to various agreements,
granted to certain of the Prepetition Lenders an aggregate royalty equal to 19.50% of the net sales and license revenues from the Biovest Biologic Products received by Biovest (the “Biovest Royalty”); and 

WHEREAS, in satisfaction of the Prepetition Debt, the cancellation of the Biovest Warrants, and the modification of the
Biovest Royalty, certain of the Prepetition Lenders have agreed to accept allowed secured claims against Biovest in the Biovest Bankruptcy Cases in the aggregate amounts of $24,900,000.00 and $4,160,000.00, respectively, and other consideration, in
accordance with the terms and conditions set forth herein and in the Confirmed Plan. 

 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual covenants and undertakings and the terms and conditions contained herein,
the parties hereto agree as follows: 
 1.      General Definitions and Terms;
Rules of Construction. 
 (a)      General Definitions. Capitalized
terms used in this Agreement shall have the meanings assigned to them in Annex A. 

(b)      Accounting Terms. Any accounting terms used in this Agreement which are not
specifically defined herein shall have the meanings customarily given them in accordance with GAAP and all financial computations in this Agreement shall be computed, unless specifically provided herein, in accordance with GAAP consistently applied.

 (c)      Other Terms. Any capitalized terms used in this Agreement and
defined in the UCC shall have the meaning given therein, unless otherwise defined herein. 

(d)      Rules of Construction. All Schedules, Addenda, Annexes and Exhibits hereto
or expressly identified to this Agreement are incorporated herein by reference and taken together with this Agreement constitute but a single agreement. The words “herein”, “hereof” and “hereunder” or other words of
similar import refer to this Agreement as a whole, including the Exhibits, Addenda, Annexes and Schedules thereto, as the same may be from time to time amended, modified, restated or supplemented in accordance with the terms of this Agreement, and
not to any particular section, subsection or clause contained in this Agreement. Wherever from the context it appears appropriate, each term stated in either the singular or the plural shall include the singular and the plural, and pronouns stated
in the masculine, feminine or neuter gender shall include the masculine, the feminine and the neuter. The term “or” is not exclusive. The term “including” (or any form thereof) shall not be limiting or exclusive. All references
to statutes and related regulations shall include any amendments of same and any successor statutes and regulations. All references in this Agreement or in the Schedules, Addenda, Annexes and Exhibits to this Agreement to sections, schedules,
disclosure schedules, exhibits, and attachments shall refer to the corresponding sections, schedules, disclosure schedules, exhibits, and attachments of or to this Agreement. All references to any instruments or agreements, including references to
this Agreement or any of the Ancillary Agreements, shall include any and all modifications or amendments thereto and any and all extensions or renewals thereof. 

(e)      This Agreement shall be subject to the terms and provisions of the Confirmed Plan.
To the extent that there is any conflict between the terms and provisions of this Agreement and the terms and provisions of the Confirmed Plan, the terms and provisions of this Agreement will control unless otherwise expressly stated in the
Confirmation Order. 
 2.      The BVTI Term Loans and Closing Shares.

 (a)      The BVTI Term Notes. 

(i)      Subject to the terms and conditions set forth herein and in the Ancillary
Agreements, at the Closing, the Lenders will receive in satisfaction of the Prepetition 

  
 2 

 
Debt, (A) secured term promissory notes of Biovest in an aggregate principal amount of $24,900,000.00 (the “Term A Notes”) and (B) secured term promissory notes of
Biovest in an aggregate principal amount of $4,160,000.00 (the “Term B Notes” and together with the Term A Notes, the “BVTI Term Notes”). The BVTI Term Notes shall be issued to the Lenders in the principal amounts
set forth on Schedule 2(a)(i) attached hereto. 
 (ii)      If Biovest at
any time fails to perform or observe any of the covenants contained in this Agreement or in any Ancillary Agreement (after any applicable grace period and/or opportunity to cure), the Agent may upon written notice to Biovest, but need not, perform
or observe such covenant on behalf and in the name, place and stead of Biovest (or, at the Agent’s option, in the Agent’s name) and may, but need not, take any and all other actions which the Agent may deem necessary to cure or correct
such failure (including the payment of Taxes, the satisfaction of Liens, the performance of obligations owed to Account Debtors, lessors or other obligors, the procurement and maintenance of insurance, the execution of assignments, security
agreements and financing statements, and the endorsement of instruments). The amount of all monies expended and all out-of-pocket costs and reasonable expenses (including attorneys’ fees and legal expenses) incurred by the Agent in connection
with or as a result of the performance or observance of such covenants or the taking of such action by the Agent shall be charged to Biovest and added to the principal amount of the BVTI Term Notes. To facilitate the Agent’s performance or
observance of such covenants by Biovest, Biovest hereby irrevocably appoints the Agent, or the Agent’s delegate, acting alone, as Biovest’s attorney in fact (which appointment is coupled with an interest) with the right (but not the duty)
from time to time to create, prepare, complete, execute, deliver, endorse or file in the name and on behalf of Biovest any and all instruments, documents, assignments, security agreements, financing statements, applications for insurance and other
agreements and writings required to be obtained, executed, delivered or endorsed by Biovest. 

(iii)      The Agent will account to Biovest monthly with a statement of all advances,
charges and payments made pursuant to this Agreement, and such account rendered by the Agent shall be deemed final, binding and conclusive, absent manifest error, unless the Agent is notified by Biovest in writing to the contrary within thirty
(30) days of the date such account was rendered specifying the item or items to which objection is made. 

(b)      Closing Shares. In addition to the issuance of the BVTI Term Notes to the
Lenders, in consideration of the cancellation of the Biovest Warrants and the modification of the Biovest Royalty, at the Closing, Biovest shall issue to certain of the Lenders an original stock certificate issued in its name evidencing such
Lender’s allocable portion of the Closing Shares, which shares shall be subject to the conditions and restrictions set forth herein and in the Closing Shares Lock-Up Agreement. The total number of Closing Shares to be issued to the Lenders will
be Fourteen Million Eight Hundred Thirty-Four Thousand Seven Hundred Eighty-Two (14,834,782), which shall be allocated among the Lenders in accordance with Schedule 2(b) attached hereto. Except for the Closing Shares, the Lenders shall not be
entitled to receive any shares of the Biovest Common Stock under this Agreement or the Accentia Security Agreement. The number and allocation of the Closing Shares to the Lenders shall be as set forth on Schedule 2(b) attached hereto.
Notwithstanding the provision in the Closing Shares Lock-Up Agreement which provides that the Seller Lenders (as such term is defined in the Closing Shares Lock-Up Agreement) are subject to Rule 144(e) of the Securities Act, Biovest hereby
acknowledges that it 

  
 3 

 
does not consider the Lenders, either individually or in the aggregate, to be an Affiliate or Affiliates of Biovest. 

3.      Repayment of the BVTI Term Loans.  The BVTI Term Loans shall be
repaid in accordance with the terms of the BVTI Term Notes and as set forth herein. Biovest may prepay the BVTI Term Loans from time to time in accordance with the terms and provisions of the BVTI Term Notes. 

4.      Reserved. 

5.      Interest and Payments. 

(a)      Interest. 

(i)      Biovest shall pay interest on the BVTI Term Loans at the rates per annum set
forth in the BVTI Term Notes. 
 (ii)      In no event shall the aggregate
interest payable hereunder or under the BVTI Term Notes exceed the maximum rate permitted under any applicable law or regulation, as in effect from time to time (the “Maximum Legal Rate”), and if any provision of this Agreement or
any Ancillary Agreement is in contravention of any such law or regulation, interest payable under this Agreement and each Ancillary Agreement shall be computed on the basis of the Maximum Legal Rate (so that such interest will not exceed the Maximum
Legal Rate). 
 (iii)      Biovest shall pay principal, interest and all other
amounts payable hereunder, or under any Ancillary Agreement, without any deduction whatsoever, including any deduction for any set-off or counterclaim. 
 (iv)      All Contract Rate payments made by Biovest under the BVTI Term Notes shall be made free and clear of, and without deduction or withholding for or on account of, any
future Taxes hereafter imposed, levied, collected, withheld or assessed by any Governmental Authority, other than Excluded Taxes. If any Non-Excluded Taxes or Other Taxes are required to be withheld from any amounts payable to any Creditor Party
hereunder, the amounts so payable to such Creditor Party shall be increased to the extent necessary to yield to such Creditor Party (after payment of all Non-Excluded Taxes and Other Taxes, including those imposed on payments made pursuant to this
paragraph (iv) of this Section 5(a)) interest or any such other amounts payable hereunder at the rates or in the amounts specified in this Agreement, provided, however, that Biovest shall not be required to increase any such
amounts payable to any Lender with respect to any Non-Excluded Taxes that are directly attributable to such Lender’s failure to comply with the requirements of paragraph (vii) of this Section 5(a); and provided, further,
however, that if Biovest is required to increase the amounts payable to any Creditor Party by reason of this Section 5(a)(iv), Biovest shall pay such increased amounts within ninety (90) days following the date on which such
Non-Excluded Taxes or Other Taxes were withheld. 

  
 4 

 (v)      In addition, subject to 11 U.S.C.
§1146(a) and the terms of the Confirmation Order, Biovest shall pay any Other Taxes to the relevant Governmental Authority in accordance with applicable law. 

(vi)      Whenever any Non-Excluded Taxes or Other Taxes are payable by Biovest, as
promptly as possible thereafter Biovest shall send to the Agent for its own account or for the account of the relevant Lender, as the case may be, a certified copy of an original official receipt received by Biovest showing payment thereof (or such
other evidence reasonably satisfactory to the Agent). If Biovest fails to pay any Non-Excluded Taxes or Other Taxes when due to the appropriate taxing authority or fails to remit to the Agent the required receipts or other required documentary
evidence, Biovest shall indemnify the Creditor Parties for any incremental taxes, interest or penalties that may become payable by any Creditor Party as a result of any such failure. 

(vii)      Each Lender (or its assignee) that is not a “United States person,”
as defined in Section 7701(a)(30) of the Code (a “Non-U.S. Lender”) shall, and hereby agrees to, deliver to Biovest and the Agent two completed originals of an appropriate U.S. Internal Revenue Service Form W-8, as applicable,
or any subsequent versions thereof or successors thereto, properly completed and duly executed by such Non-U.S. Lender. Such forms shall be delivered by each Non-U.S. Lender on or before the date it becomes a party to this Agreement. In addition,
each Non-U.S. Lender shall deliver such forms promptly upon the obsolescence or invalidity of any form previously delivered by such Non-U.S. Lender. Each Non-U.S. Lender shall promptly notify Biovest at any time it determines that it is no longer in
a position to provide any previously delivered certificate to Biovest (or any other form of certification adopted by the U.S. taxing authorities for such purpose). Notwithstanding any other provision of this paragraph, a Non-U.S. Lender shall not be
required to deliver any form pursuant to this paragraph that such Non-U.S. Lender is not legally able to deliver. 
 (viii)      The agreements in this Section 5(a) shall survive the termination of this Agreement and the payment of the BVTI Term Loans and all other amounts payable
hereunder or under any other Ancillary Agreement. 
 (b)      Failure to
Provide Financial Information. Without affecting the Lenders’ rights and remedies, in the event Biovest fails to deliver the financial information required by Section 11 on or before the dates set forth therein, Biovest shall pay each
Lender its pro rata share of an aggregate fee in the amount of $250.00 per week (or portion thereof) for each such failure until the missing financial information is delivered to the Agent. All amounts incurred pursuant to this Section 5(b)
shall be due and payable upon receipt by Biovest of an invoice from the Agent for such amounts, which shall be paid monthly, in arrears, on the first Business Day of each calendar month. 

6.      Security Interest. 

(a)      Subject only to the Permitted Liens, to secure the prompt payment to the Creditor
Parties of the Obligations, Biovest hereby assigns, pledges and grants to the Agent, for the ratable benefit of the Creditor Parties, a continuing security interest in and Lien upon all of the Collateral. All of Biovest’s Books and Records
relating to the Collateral shall, until 

  
 5 

 
delivered to or removed by the Agent, be kept by Biovest in trust for the Creditor Parties until the termination of this Agreement and the payment in full of all Obligations. Each confirmatory
assignment schedule or other form of assignment hereafter executed by Biovest shall be deemed to include the foregoing grant, whether or not the same appears therein. Notwithstanding the foregoing, the continuing security interests in and Lien upon
the Collateral, as provided for herein, shall terminate upon the payment in full of the BVTI Term Notes and all interest, fees, costs, charges, expenses, or other sums payable hereunder and under any Ancillary Agreements (other than the Biovest
Contingent Payment Agreement). 
 (b)      Biovest hereby (i) authorizes the
Agent to file any financing statements, continuation statements or other amendments thereto that (A) indicate the Collateral (1) as all assets and personal property of Biovest or words of similar effect, regardless of whether any
particular asset comprised in the Collateral falls within the scope of Article 9 of the UCC of the applicable jurisdiction, or (2) as being of an equal or lesser scope or with greater detail, and (B) contain any other information required
by Part 5 of Article 9 of the UCC for the sufficiency or filing office acceptance of any financing statement, continuation statement or other amendment and (ii) ratifies its authorization for the Agent to have filed any initial financial
statements, or amendments thereto if filed prior to the date hereof. Except as otherwise provided in the Confirmed Plan, Biovest acknowledges that it is not authorized to file and, except as expressly set forth in this Agreement, will not give any
authorization to anyone other than the Agent (including pursuant to Section 9-509(b) of the UCC) to file, any financing statement or amendment or termination statement with respect to any financing statement without the prior written consent of
the Agent and agrees that it will not do so without the prior written consent of the Agent, subject to Biovest’s rights under Section 9-509(d)(2) of the UCC. 

(c)      Biovest hereby grants to the Agent, for the ratable benefit of the Creditor
Parties, an irrevocable, non-exclusive, worldwide license without payment of royalty or other compensation to Biovest, upon the occurrence and during the continuance of an Event of Default, to use or otherwise exploit in any manner as to which
authorization of the holder of such Intellectual Property would be required, and to license or sublicense such rights in, to and under any Intellectual Property now or hereafter owned by or licensed to Biovest, and wherever the same may be located,
and including in such license access to all media in which any of such Intellectual Property may be recorded or stored and to all software and hardware used for the compilation or printout thereof. Biovest represents, promises and agrees that any
such license or sublicense is not and will not be in conflict with the contractual or commercial rights of any third Person and subject, in the case of trademarks and service marks, to sufficient rights to quality control and inspection in favor of
Biovest to avoid the right of invalidation of said trademarks and service marks. The foregoing license and sublicense will terminate on the termination of this Agreement and the payment in full of the Obligations; provided, however,
that any license, sublicense, or other rights granted by the Agent pursuant to such license during its term in connection with any enforcement of remedies by Agent hereunder shall remain in effect in accordance with its terms. 

(d)      Any proceeds received by the Agent from the foreclosure, sale, lease or other
disposition of any of the Collateral shall be paid over to the Lenders for application in accordance with Section 21. 

  
 6 

 7.      Representations, Warranties and
Covenants Concerning the Collateral. Biovest represents, warrants and covenants as of the date hereof as follows: 
 (a)      All of the Collateral (i) is owned by it free and clear of all Liens (including any claim of infringement) except those in the Agent’s favor and Permitted
Liens and (ii) is not subject to any agreement prohibiting the granting of a Lien or requiring notice of or consent to the granting of a Lien. 
 (b)      It shall not encumber, mortgage, pledge, assign or grant any security interest in or Lien upon any Collateral to anyone other than the Agent and the other Creditor
Parties and except for Permitted Liens. 
 (c)      The Liens granted pursuant to
this Agreement, upon the filing of UCC-1 financing statements in respect of Biovest in favor of the Agent in the applicable filing office of the state of organization of Biovest, the recording of the Liens in favor of the Agent in the U.S. Patent
and Trademark Office and the U.S. Copyright Office, as applicable, the taking of any actions required under the laws of jurisdictions outside the United States with respect to Intellectual Property included in the Collateral which is created under
such laws, and the completion of the other filings and actions listed on Schedule 7(c) attached hereto, have been delivered to the Agent in duly executed form, constitute valid perfected security interests in all of the Collateral in favor of
the Agent as security for the payment of the Obligations, enforceable in accordance with the terms hereof against any and all of Biovest’s creditors and purchasers and such security interests are prior to all other Liens in existence on the
date hereof except those relating to the Permitted Liens, which, pursuant to the Confirmed Plan, are senior in priority to the Liens granted in favor of the Agent under this Agreement. 

(d)      No effective security agreement, mortgage, deed of trust, financing statement,
equivalent security or Lien instrument or continuation statement covering all or any part of the Collateral is on file or of record in any public office, except those relating to Permitted Liens. 

(e)      It shall not dispose of any of the Collateral whether by sale, lease or otherwise
except for Permitted Liens, the sale of Inventory or license of Intellectual Property in the ordinary course of business, and the disposition or transfer in the ordinary course of business during any fiscal year of obsolete and worn-out Equipment
having an aggregate fair market value of not more than $50,000 or to the extent that (i) the proceeds of any such disposition are used to acquire replacement Equipment which is subject to the Agent’s first priority security interest or are
used to repay BVTI Term Loans or to pay general corporate expenses, or (ii) following the occurrence of an Event of Default which continues to exist, the proceeds of which are remitted to the Agent to be held as cash collateral for the
Obligations. 
 (f)      It shall defend the right, title and interest of the
Agent in and to the Collateral against the claims and demands of all Persons whomsoever, and take such actions, including (i) all actions necessary to grant the Agent “control” of any Investment Property, Deposit Accounts,
Letter-of-Credit Rights or electronic Chattel Paper owned by Biovest, with any agreements establishing control to be in form and substance satisfactory to the Agent, (ii) the prompt (but in no event later than five (5) Business Days
following the Agent’s request therefor) 

  
 7 

 
delivery to the Agent of all original Instruments, Chattel Paper, negotiable Documents and certificated Equity Interests owned by it (in each case, accompanied by stock powers, allonges or other
instruments of transfer executed in blank), (iii) notification to third parties of the Agent’s interest in the Collateral at the Agent’s request, and (iv) the institution of litigation against third parties as shall be prudent in
order to protect and preserve its and/or the Agent’s respective and several interests in the Collateral. 

(g)      It shall promptly, and in any event within five (5) Business Days after the
same is acquired by it, notify the Agent of any Commercial Tort Claim acquired by it and, unless otherwise consented to by the Agent, it shall enter into a supplement to this Agreement granting to the Agent a Lien in such Commercial Tort Claim.

 (h)      It shall place notations upon its Books and Records and any of its
financial statements to disclose the Agent’s Lien in the Collateral. 

(i)      Subject to any Permitted Liens, if it retains possession of any Chattel Paper or
Instrument with the Agent’s consent, such Chattel Paper and Instruments shall be marked with the following legend: “This writing and obligations evidenced or secured hereby are subject to the security interest of LV Administrative
Services, Inc., as agent.” Notwithstanding the foregoing, upon the reasonable request of the Agent, such Chattel Paper and Instruments shall be delivered to the Agent. 

(j)      It shall perform in a reasonable time all other steps requested by the Agent to
create and maintain in the Agent’s favor a valid perfected first Lien in all Collateral subject only to Permitted Liens, which, pursuant to the Confirmed Plan, are senior in priority to the Liens granted in favor of the Agent under this
Agreement. 
 (k)      It shall keep and maintain its Equipment in good operating
condition, except for ordinary wear and tear, and shall make all necessary repairs and replacements thereof so that the value and operating efficiency shall at all times be maintained and preserved. It shall not permit any such items to become a
Fixture to real estate or accessions to other personal property. 
 (l)      It
shall maintain and keep all of its Books and Records concerning the Collateral at its executive offices listed in Schedule 12(n). 
 (m)      It shall maintain and keep the tangible Collateral at the addresses listed in Schedule 12(n); provided, that (i) it may change such locations or open a
new location if it provides the Agent at least thirty (30) days prior written notice of such changes or new location and (ii) prior to such change or opening of a new location where Collateral having a value of more than $50,000 will be
located, it executes and delivers to the Agent such agreements as are deemed reasonably necessary or prudent by the Agent, including landlord agreements, mortgagee agreements and warehouse agreements, each in form and substance satisfactory to the
Agent, to adequately protect and maintain the Agent’s security interest in such Collateral. 

(n)      Schedule 7(n) attached hereto lists all banks and other financial
institutions at which it maintains deposits and/or other accounts, and such Schedule 7(n) correctly identifies the name, address and telephone number of each such depository, the name in

  
 8 

 
which the account is held, and the complete account number. It shall not establish any depository or other bank account with any financial institution (other than the accounts set forth on
Schedule 7(n)) without the Agent’s prior written consent. 

(o)      Its exact legal name (as indicated in the public record of its jurisdiction of
organization), jurisdiction of organization, organizational identification number, if any, from the jurisdiction of organization, and the location of its chief executive office or sole place of business or principal residence, as the case may be,
are specified on Schedule 7(o) attached hereto. It has furnished to the Agent a certified charter, certificate of incorporation or other organization document and long-form good standing certificate as of a date which is recent to the date
hereof. It is organized solely under the law of the jurisdiction so specified and has not filed any certificates of domestication, transfer or continuance in any other jurisdiction. Except as specified on Schedule 7(o), it has not changed its
name, jurisdiction of organization, chief executive office or sole place of business or its corporate structure in any way (e.g., by merger, consolidation, change in corporate form or otherwise) within the past five years and has not within the last
five years become bound (whether as a result of merger or otherwise) as a grantor under a security agreement entered into by another Person, which has not heretofore been terminated. 

(p)      It will not, except upon 30 days’ prior written notice to the Agent and
delivery to the Agent of (i) all additional financing statements and other documents reasonably requested by the Agent to maintain the validity, perfection and priority of the security interests provided for herein and (ii) if applicable,
a written supplement to Schedule 12(n) showing any additional location at which Inventory or Equipment in excess of $50,000 in the aggregate shall be kept: (A) change its jurisdiction of organization or the location of its chief
executive office or sole place of business or principal residence from that referred to in Section 7(o); (B) change its name, identity or organizational structure; or (C) permit any of the Inventory or Equipment in excess of $50,000
in the aggregate to be kept at a location other than those listed on Schedule 12(n). 

8.      Payment of Accounts.  At the Agent’s election, following the
occurrence of an Event of Default which is continuing, the Agent may notify Biovest’s Account Debtors of the Agent’s security interest in the Accounts, collect them directly and charge the collection costs and reasonable expenses thereof
to Biovest. 
 9.      Reserved. 

10.      Inspections and Appraisals.  At all times during normal business
hours, the Agent, and/or any agent of the Agent, shall have the right to (a) have access to, visit, inspect, review, evaluate and make physical verification and appraisals of Biovest’s properties and the Collateral, (b) inspect, copy
(or take originals if necessary) and make extracts from Biovest’s Books and Records, including management letters prepared by the Accountants, and (c) discuss with Biovest’s directors, principal officers, and Accountants,
Biovest’s business, assets, liabilities, financial condition, results of operations and business prospects. So long as no Default or Event of Default has occurred and is continuing, such inspection and appraisal rights shall be limited to twice
per year. Biovest will deliver to the Agent any instrument necessary for the Agent to obtain records from any service bureau maintaining records for Biovest. If any internally 

  
 9 

 
prepared financial information is unsatisfactory in any manner to the Agent, the Agent may request that the Accountants review the same. 

11.      Financial Reporting.  Biovest will deliver, or cause to be
delivered, to the Agent each of the following, which shall be in form and detail acceptable to the Agent (with the filing of such information with the SEC pursuant to and in accordance with SEC rules and regulations to be deemed delivery to the
Agent for purposes hereof): 
 (a)      As soon as available and in any event
within one hundred five (105) days after the end of each fiscal year of Biovest, Biovest’s audited annual financial statements with a report of independent certified public accountants of recognized standing selected by Biovest and
acceptable to the Agent (the “Accountants”), which annual financial statements shall be without qualification (other than a going-concern qualification, if applicable) and shall include Biovest’s balance sheet as at the end of
such fiscal year and Biovest’s related statement of income, retained earnings and cash flows for the fiscal year then ended, prepared on a consolidating and consolidated basis to include Biovest and each of its affiliates, all in reasonable
detail and prepared in accordance with GAAP. Biovest will also deliver to the Agent at such time, if available, copies of any management letters prepared by the Accountants; 

(b)      As soon as available and in any event within fifty (50) days after the end of
each fiscal quarter that is not a fiscal year end of Biovest, an unaudited/internal balance sheet and statements of income, retained earnings and cash flows of Biovest as at the end of and for such quarter and for the year to date period then ended,
prepared on a consolidating and consolidated basis to include Biovest and its affiliates, in reasonable detail and stating in comparative form the figures for the corresponding date and periods in the previous year, all prepared in accordance with
GAAP, subject to year-end adjustments and accompanied by a certificate of Biovest’s president, chief executive officer or chief financial officer stating that such financial statements have been prepared in accordance with GAAP, subject to
year-end audit adjustments; 
 (c)      As soon as available and in any event
within twenty-five (25) days after the end of each calendar month, an unaudited/internal balance sheet and statements of income, retained earnings and cash flows of Biovest as at the end of and for such month and for the year to date period
then ended, prepared on a consolidating and consolidated basis to include Biovest and each of its affiliates, in reasonable detail and stating in comparative form the figures for the corresponding date and periods in the previous year, all prepared
in accordance with GAAP, subject to year-end adjustments and accompanied by a certificate of Biovest’s president, chief executive officer or chief financial officer stating that such financial statements have been prepared in accordance with
GAAP, subject to year-end audit adjustments; and 
 (d)      Such other financial
information as to Biovest as the Agent shall reasonably request. 

12.      Additional Representations and Warranties.  Biovest hereby
represents and warrants to each Creditor Party as of the date hereof as follows: 

  
 10 

 (a)      Organization, Good Standing and
Qualification.  It is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. It has the corporate power and authority to own and operate its properties and assets and, insofar as it
is or shall be a party thereto, to (i) execute and deliver this Agreement and the Ancillary Agreements, (ii) issue the BVTI Term Notes and the Closing Shares, and (iii) carry out the provisions of this Agreement and the Ancillary
Agreements and to carry on its business as presently conducted. It is duly qualified and is authorized to do business and is in good standing as a foreign corporation in all jurisdictions in which the nature or location of its activities and of its
properties (both owned and leased) makes such qualification necessary, except for those jurisdictions in which the failure to do so has not had, or could not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. 
 (b)      Subsidiaries.  Each direct and indirect
Subsidiary of Biovest and its percentage ownership thereof is set forth on Schedule 12(b) attached hereto. 
 (c)      Capitalization; Voting Rights. 
 (i)      The authorized capital stock of Biovest consists of 350,000,000 shares, of which (A) 300,000,000 are shares of Biovest Common Stock, 98,149,783 shares of which
are issued and outstanding (not taking into account the shares of Biovest Common Stock that may be issued or are issuable pursuant to the Confirmed Plan), and (B) 50,000,000 are shares of preferred stock, par value $.01 per share, none of which
are issued and outstanding. 
 (ii)      Except for (A) as disclosed on
Schedule 12(c), (B) the shares of Biovest Common Stock that may be issued or are issuable pursuant to the Confirmed Plan, including those that may be issued to the Investor DIP Lenders, and (C) the Closing Shares that will be issued
pursuant to this Agreement and the Ancillary Agreements, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal), proxy or stockholder agreements, or arrangements or agreements of
any kind for the purchase or acquisition from Biovest of any of its securities. Except as disclosed on Schedule 12(c) or as provided in the Confirmed Plan, neither the offer or issuance of any of the BVTI Term Notes or the Closing Shares, nor
the consummation of any transaction contemplated hereby, will result in a change in the price or number of any securities of Biovest outstanding, under anti-dilution or other similar provisions contained in or affecting any such securities.

 (iii)      All issued and outstanding shares of Biovest Common Stock:
(A) have been duly authorized and validly issued and are fully paid and non-assessable; and (B) were issued in compliance with all applicable state and federal laws concerning the issuance of securities. 

(iv)      The rights, preferences, privileges and restrictions of the Biovest Common Stock
are as stated in Biovest’s Charter. When issued in compliance with the provisions of this Agreement and Biovest’s Charter, the Closing Shares will be validly issued, fully paid and non-assessable, and free of any Liens. 

(d)      Authorization; Binding Obligations.  All corporate action on its
part (including of its officers and directors) necessary for the authorization of this Agreement and the 

  
 11 

 
Ancillary Agreements, the performance of all of its obligations hereunder and under the Ancillary Agreements on the Closing Date, and the authorization, issuance and delivery of the BVTI Term
Notes and the Closing Shares has been taken or will be taken prior to the Closing Date. This Agreement and the Ancillary Agreements, when executed and delivered and to the extent it is a party thereto, will be its valid and binding obligations
enforceable against it in accordance with their terms, except: 
 (i)      as
limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights; and 

(ii)      general principles of equity that restrict the availability of equitable or
legal remedies. 
 The issuance of the BVTI Term Notes and the Closing Shares are not and will not be subject to any preemptive
rights or rights of first refusal that have not been properly waived or complied with. 

(e)      Liabilities.  Except for (i) the BVTI Term Notes and any of
the Indebtedness hereunder and under the Ancillary Agreements, (ii) the allowed and disputed claims of creditors of Biovest, Biovax, Inc., AutovaxID, Inc., Biolender, LLC and Biolender II, LLC in the Biovest Bankruptcy Cases (including the
allowed claim of the Exit Lender), and (iii) liabilities incurred in the ordinary course of business, it does not have any liabilities nor is it indebted to any Person. 

(f)      Agreements; Action. 

(i)      It maintains disclosure controls and procedures (“Disclosure
Controls”) designed to ensure that information required to be disclosed by Biovest in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the
rules and forms of the SEC. 
 (ii)      It makes and keeps books, records, and
accounts that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of its assets. It maintains internal control over financial reporting (“Financial Reporting Controls”) designed by, or under the
supervision of, its principal executive and principal financial officers, and effected by its board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with GAAP. 

(g)      Title to Properties and Assets; Liens, Etc.  Except as set forth
on Schedule 12(g) attached hereto and except as otherwise contemplated by the Confirmed Plan, it has good and marketable title to its properties and assets (tangible or intangible), and good title to its leasehold interests, in each case
subject to no Lien, other than Permitted Liens. All facilities, Equipment, Fixtures, vehicles and other properties owned, leased or used by it are in good operating condition and repair and are reasonably fit and usable for the purposes for which
they are being used, subject to normal wear and tear. 

  
 12 

 (h)      Registration Rights and Voting
Rights.  Except (i) as set forth on Schedule 12(h) attached hereto, (ii) as disclosed in Exchange Act Filings, and (iii) as disclosed in the Confirmed Plan or in the Bankruptcy Cases, it is not presently under any
obligation, nor has it granted any rights, to register any of its presently outstanding securities or any of its securities that may hereafter be issued. Except as set forth on Schedule 12(h) and except as disclosed in Exchange Act Filings,
to its knowledge, none of its stockholders has entered into any agreement with respect to its voting of equity securities of Biovest. 
 (i)      Compliance with Laws; Permits.  No governmental orders, permissions, consents, approvals or authorizations are required to be obtained, and no
registrations or declarations are required to be filed, in connection with the execution and delivery of this Agreement or any Ancillary Agreement and the issuance of the BVTI Term Notes or the Closing Shares, except for such as have been duly and
validly obtained or filed and except for the Compromise Order, or with respect to any filings that must be made after the Closing Date, which will be filed in a timely manner. It has all material franchises, permits, licenses and any similar
authority necessary for the conduct of its business as now being conducted by it, the lack of which could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

(j)      Valid Offering.  Assuming the accuracy of the representations and
warranties of the Lenders contained in this Agreement, the offer and sale of the BVTI Term Notes and the Closing Shares will be exempt from the registration requirements of the Securities Act, and will have been registered or qualified (or are
exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable state securities laws. 
 (k)      No Integrated Offering.  Neither it, nor any of its Affiliates, nor any Person acting on its or their behalf, has directly or indirectly made any
offers or sales of any security or solicited any offers to buy any security under circumstances that would cause the offering of the BVTI Term Notes or the Closing Shares pursuant to this Agreement or any Ancillary Agreement to be integrated with
prior offerings by it for purposes of the Securities Act which would prevent it from issuing the BVTI Term Notes or the Closing Shares pursuant to Rule 506 under the Securities Act, or any applicable exchange-related stockholder approval provisions.
Neither it nor any of its Affiliates will take any action or steps that would cause the offering of the BVTI Term Notes or the Closing Shares to be integrated with other offerings. 

(l)      Stop Transfer.  The Closing Shares and any Conversion Shares that
may be issued will be issued pursuant to Section 1145(a) of the Bankruptcy Code. It will not issue any stop transfer order or other order impeding the sale and delivery of any of the Closing Shares or any of the Conversion Shares as may be
permitted pursuant to the terms of the Closing Shares Lock-Up Agreement and the BVTI Term Notes, or at such time as the Closing Shares or the Conversion Shares are registered for public sale or an exemption from registration is available, except as
required by state and federal securities laws. 
 (m)      Patriot
Act.  It certifies that, to the best of its knowledge, it has not been designated, nor is or shall be owned or controlled, by a “suspected terrorist” as defined in Executive Order 13224. It hereby acknowledges that each of
the Creditor Parties seeks to comply with all applicable laws concerning money laundering and related activities. In 

  
 13 

 
furtherance of those efforts, it hereby represents, warrants and covenants that: (i) none of the cash or property that it will pay or will contribute to any Creditor Party has been or shall
be derived from, or related to, any activity that is deemed criminal under United States law; and (ii) no contribution or payment by it to any Creditor Party, to the extent that they are within its control, shall cause such Creditor Party to be
in violation of the United States Bank Secrecy Act, the United States International Money Laundering Control Act of 1986 or the United States International Money Laundering Abatement and Anti-Terrorist Financing Act of 2001. It shall promptly notify
the Agent if any of these representations, warranties and covenants ceases to be true and accurate regarding it. It shall provide any Creditor Party with any additional information regarding it that such Creditor Party deems necessary or convenient
to ensure compliance with all applicable laws concerning money laundering and similar activities. It understands and agrees that if at any time it is discovered that any of the foregoing representations, warranties and covenants are incorrect, or if
otherwise required by applicable law or regulation related to money laundering or similar activities, the Creditor Parties may undertake appropriate actions to ensure compliance with applicable law or regulation, including but not limited to
segregation and/or redemption of any Lender’s investment in it. It further understands that the Creditor Parties may release confidential information about it and, if applicable, any underlying beneficial owners, to proper authorities if such
Creditor Party, in its sole discretion, determines that it is in the best interests of such Creditor Party in light of relevant rules and regulations under the laws set forth in subsection (ii) above. 

(n)      Name; Locations of Offices, Records and Collateral.  Schedule
12(n) attached hereto sets forth Biovest’s name as it appears in official filings in the jurisdiction of its organization, the type of entity of Biovest, the organizational identification number issued by Biovest’s jurisdiction of
organization or a statement that no such number has been issued, Biovest’s jurisdiction of organization, and the location of Biovest’s chief executive office, corporate offices, warehouses, other locations of Collateral and locations where
records with respect to Collateral are kept (including in each case the county of such locations) and, except as set forth in such Schedule 12(n), such locations have not changed during the preceding twelve months. As of the Closing Date,
during the prior five years, except as set forth in Schedule 12(n), Biovest has not been known as or conducted business in any other name (including trade names). Biovest has only one state of organization. 

(o)      Status of Obligations.  All of the Obligations shall be reported
as debt for U.S. federal income tax purposes on all applicable tax returns filed by Biovest, and Biovest shall not take a position on any tax return or in any judicial or administrative proceeding that is inconsistent with such characterization
(unless otherwise required by law). 

13.      Covenants.  Biovest covenants and agrees with the Creditor
Parties as of the date hereof as follows: 
 (a)      Stop
Orders.  Biovest shall advise the Agent, promptly after it receives notice of issuance by the SEC, any state securities commission or any other regulatory authority, of any stop order or of any order preventing or suspending any
offering of any securities of Biovest, or of the suspension of the qualification of the Biovest Common Stock for offering or sale in any jurisdiction, or the initiation of any proceeding for any such purpose. 

  
 14 

 (b)      Listing.  Biovest
shall promptly secure the listing or quotation, as applicable, of the Closing Shares on the Principal Market upon which shares of Biovest Common Stock are listed or quoted, as applicable (subject to official notice of issuance), and shall maintain
such listing or quotation, as applicable, so long as any other shares of Biovest Common Stock shall be so listed or quoted, as applicable. Biovest shall maintain the listing or quotation, as applicable, of the Biovest Common Stock on the Principal
Market, and will comply in all material respects with Biovest’s reporting, filing and other obligations under the bylaws or rules of the Financial Industry Regulatory Authority (“FINRA”) and such exchanges, as applicable.

 (c)      Market Regulations.  Biovest shall notify the SEC,
FINRA and applicable state authorities, in accordance with their requirements, of the transactions contemplated by this Agreement, and shall take all other necessary action and proceedings as may be required and permitted by applicable law, rule and
regulation for the legal and valid issuance of the BVTI Term Notes and the Closing Shares to the Lenders and promptly provide copies thereof to the Agent. 
 (d)      Reporting Requirements.  Biovest shall file with the SEC all reports required to be filed pursuant to the Exchange Act and refrain from terminating
its status as an issuer required by the Exchange Act to file reports thereunder even if the Exchange Act or the rules or regulations thereunder would permit such termination. 

(e)      Insurance. 

(i)      Biovest shall bear the full risk of loss from any loss of any nature whatsoever
with respect to the Collateral and Biovest and each of its Subsidiaries will, jointly and severally, bear the full risk of loss from any loss of any nature whatsoever with respect to the Collateral pledged to the Agent as security for the
Obligations. Furthermore, Biovest will insure or cause the Collateral to be insured in the Agent’s name as an additional insured and lender loss payee, with an appropriate loss payable endorsement in form and substance satisfactory to the
Agent, against loss or damage by fire, flood, sprinkler leakage, theft, burglary, pilferage, loss in transit and other risks customarily insured against by companies in similar businesses similarly situated as Biovest and its Subsidiaries, including
but not limited to workers compensation, public and product liability and business interruption, and such other hazards as the Agent shall specify in amounts and under insurance policies and bonds by insurers acceptable to the Agent and all premiums
thereon shall be paid by Biovest and the policies delivered to the Agent. If Biovest fails to obtain the insurance and in such amounts of coverage as otherwise required pursuant to this Section 13(e), the Agent may procure such insurance and
the cost thereof shall be promptly reimbursed by Biovest and shall constitute Obligations. 

(ii)      Biovest’s insurance coverage shall not be impaired or invalidated by any
act or neglect of Biovest and the insurer will provide the Agent with no less than thirty (30) days notice prior to cancellation. 
 (iii)      The Agent, in connection with its status as a lender loss payee, will be assigned at all times, subject to the prior lien of the Exit Lender and any Permitted
Liens, which, pursuant to the Confirmed Plan, are senior in priority to the Liens granted in favor of the 

  
 15 

 
Agent under this Agreement, a first lien position as to any insurance policy and the proceeds thereof until such time as all Obligations have been indefeasibly satisfied in full. 

(f)      Intellectual Property.  Biovest: 

(i)      shall maintain in full force and effect its existence, rights and franchises and
all licenses and other rights to own or use its Intellectual Property, including registrations and applications therefor, that are necessary to the conduct of its business, as now conducted or as presently proposed to be conducted, and shall not do
any act or omit to do any act whereby any of such Intellectual Property may lapse, or become abandoned, dedicated to the public, or unenforceable, or the Lien therein in favor of the Agent for the ratable benefit of the Creditor Parties would be
adversely affected; 
 (ii)      shall report to the Agent (A) the filing of
any application to register a copyright no later than ten (10) days after such filing occurs, and (B) the filing of any application to register any other Intellectual Property with any other Intellectual Property registry, and the issuance
thereof, no later than thirty (30) days after such filing or issuance occurs and, in each case, shall, simultaneously with such report, deliver to the Agent fully-executed documents required to acknowledge, confirm, register, record or perfect
the Lien in such Intellectual Property. In addition, Biovest will cooperate with the Agent in effecting any amendment to this Agreement or any Ancillary Agreement to include any new item of Intellectual Property included in the Collateral;

 (iii)      shall, promptly upon the reasonable request of the Agent, execute
and deliver to the Agent any document or instrument required to acknowledge, confirm, register, record, or perfect the Lien of the Agent in any part of the Intellectual Property owned by Biovest; and 

(iv)      shall not sell, assign, transfer, license, grant any option, or create or suffer
to exist any Lien upon or with respect to Intellectual Property, except for the Liens in favor of the Agent and the Permitted Liens and except for any license of Intellectual Property in the ordinary course of its business. 

(g)      Properties.  It shall keep its properties in good repair, working
order and condition, reasonable wear and tear excepted, and from time to time make all needful and proper repairs, renewals, replacements, additions and improvements thereto; and it shall at all times comply with each provision of all leases to
which it is a party or under which it occupies property if the breach of such provision could reasonably be expected to have a Material Adverse Effect. 
 (h)      Confidentiality.  Except pursuant to the Confirmed Plan or as otherwise required in connection with the Bankruptcy Cases, Biovest will not disclose,
nor will it include in any public announcement, the name of any Creditor Party, unless expressly agreed to by such Creditor Party or unless and until such disclosure is required by law or applicable regulation, and then only to the extent of such
requirement. Notwithstanding the foregoing, Biovest may disclose any Creditor Party’s identity and the terms of this Agreement and the Ancillary Agreements to its current and prospective debt and equity financing sources. 

  
 16 

 (i)      Reissuance of
Certificates.  Biovest shall reissue certificates representing the Closing Shares or any Conversion Shares without the legends set forth in Section 41 below as follows: 

(i)      at such time as the holder thereof is permitted to dispose of the Closing Shares
or any Conversion Shares pursuant to Rule 144(e) under the Securities Act and the terms of the Closing Shares Lock-Up Agreement; or 
 (ii)      upon resale subject to an effective registration statement after the Closing Shares or any Conversion Shares are registered under the Securities Act. 

Biovest agrees to cooperate with the Lenders in connection with all resales pursuant to Rule 144(e) and, at Biovest’s expense, to
provide legal opinions necessary to allow such resales provided Biovest and its counsel receive reasonably requested representations from the Lenders and broker, if any. 

(j)      Legal Name, Etc.  It shall not, without providing the Agent with
thirty (30) days prior written notice, change (i) its name as it appears in the official filings in the jurisdiction of its organization, (ii) the type of legal entity it is, (iii) its organization identification number, if any,
issued by its jurisdiction of organization, (iv) its jurisdiction of organization, or (v) its certificate of incorporation, by-laws or other organizational document. 

(k)      Compliance with Laws.  The operation of its business is and shall
continue to be in compliance in all material respects with all applicable federal, state and local laws, rules and ordinances, including all laws, rules, regulations and orders relating to taxes, payment and withholding of payroll taxes, employer
and employee contributions and similar items, securities, employee retirement and welfare benefits, employee health and safety and environmental matters. 
 (l)      Notices.  It shall promptly inform the Agent in writing of:  (i) the commencement of all proceedings and investigations by or before,
and/or the receipt of any notices from, any governmental or nongovernmental body and all actions and proceedings in any court or before any arbitrator against or in any way concerning any event which could reasonably be expected to have, singly or
in the aggregate, a Material Adverse Effect; (ii) any change which has had, or could reasonably be expected to have, a Material Adverse Effect; and (iii) any Event of Default or Default. 

(m)      FIRPTA.  It is not a “United States real property holding
corporation” as such term is defined in Section 897(c)(2) of the Code and Treasury Regulation Section 1.897-2 promulgated thereunder, and it and each of its Subsidiaries shall at no time take any action or otherwise acquire any
interest in any asset or property to the extent the effect of which shall cause it and/or such Subsidiary, as the case may be, to be a “United States real property holding corporation” as such term is defined in Section 897(c)(2) of
the Code and Treasury Regulation Section 1.897-2 promulgated thereunder. 

(n)      Accentia Loans or Capital Contributions to
Biovest.  Notwithstanding anything to the contrary contained in this Agreement or in any of the Ancillary Agreements, Biovest shall be permitted to incur indebtedness to Accentia and accept contributions of capital

  
 17 

 
from Accentia only so long as Accentia and Biovest both comply with Section 2.2 of the Accentia Term Notes and the BVTI Term Notes, respectively, and which indebtedness to Accentia shall be
subject to the terms of the Accentia Subordination Agreement. 

14.      Closing and Conditions to Closing. 

 (a)      Closing Date.  Subject to the
satisfaction of the conditions set forth in Sections 14(e), (f) and (g) hereof (or the waiver thereof by the party entitled to waive that condition), the closing of the transactions contemplated by this Agreement (the
“Closing”) shall take place at the offices of Cole, Schotz, Meisel, Forman & Leonard, P.A., 900 Third Avenue, 16th Floor, New York, New York 10022 (or at such other place as the parties may designate in writing) at 10:00 a.m.
(Eastern Standard Time) on the date on which the conditions set forth in Sections 14(e), (f) and (g) are satisfied or waived (other than conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or
waiver of such conditions), unless another time or date, or both, are agreed to in writing by the parties hereto. The date on which the Closing shall be held is referred to in this Agreement as the “Closing Date.” 

 (b)      Deliveries by Biovest.  At the Closing, Biovest shall
deliver to the Agent: 
 (i)      the executed BVTI Term Notes in the form
attached hereto as Exhibit B; 
 (ii)      the executed Accentia Limited
Guaranty in the form attached hereto as Exhibit C; 
 (iii)      the
executed Accentia Subordination Agreement in the form attached hereto as Exhibit D; 

(iv)      the executed Exit Lender Subordination Agreement in the form attached as
Exhibit E; 
 (v)      the executed Accentia Pledge Agreement in the form
attached hereto as Exhibit F; 
 (vi)      the executed Analytica Security
Agreement in the form attached hereto as Exhibit G; 
 (vii)      the
executed Analytica Guaranty in the form attached hereto as Exhibit H; 

(viii)      the executed Closing Shares Lock-Up Agreement in the form attached hereto as
Exhibit I; 
 (ix)      the executed Biovest Contingent Payment Agreement
in the form attached hereto as Exhibit J; 
 (x)      the executed
Intellectual Property Security Agreements in the forms attached hereto as Exhibit K; 

  
 18 

 (xi)      the executed Biovest Amendments to
Organizational Documents in the form attached hereto as Exhibit L; 

(xii)      the executed Royalty Assignment Termination Agreement in the form attached
hereto as Exhibit M; 
 (xiii)      the executed AutovaxID Royalty
Termination Agreement in the form attached hereto as Exhibit N; 

(xiv)      the executed Warrant Termination Agreements in the forms attached hereto as
Exhibit O; 
 (xv)      the executed Royalty Termination Agreements in the
forms attached hereto as Exhibit P; 
 (xvi)      the executed Accentia
Royalty Termination Agreement in the form attached hereto as Exhibit Q; and 

(xvii)      such other documents and instruments as the Agent shall reasonably request.

  (c)      Deliveries by the Agent and the Lenders.  At
the Closing, the Agent and the Lenders, as applicable, shall deliver to Biovest: 

(i)      the executed Accentia Limited Guaranty; 

(ii)      the executed Accentia Subordination Agreement; 

(iii)      the executed Exit Lender Subordination Agreement; 

(iv)      the executed Accentia Pledge Agreement; 

(v)      the executed Analytica Security Agreement; 

(vi)      the executed Closing Shares Lock-Up Agreement; 

(vii)      the executed Biovest Contingent Payment Agreement; 

(viii)      the executed Intellectual Property Security Agreements; 

(ix)      the executed Royalty Assignment Termination Agreement; 

(x)      the executed AutovaxID Royalty Termination Agreement; 

(xi)      the executed Warrant Termination Agreements; 

(xii)      the executed Royalty Termination Agreements; 

(xiii)      the executed Accentia Royalty Termination Agreement; 

  
 19 

 (xiv)      written acknowledgment of the
withdrawal of any proofs of claim filed by the Creditor Parties against Biovest, Biovax, Inc., AutovaxID, Inc., Biolender, LLC, and Biolender II, LLC in the Biovest Bankruptcy Cases; and 

(xv)      such other documents and instruments as Biovest shall reasonably request.

 (d)      Termination of Agreement.  This Agreement may be
terminated prior to the Closing as follows: 
 (i)      by Biovest or the Agent,
if the Closing shall not have occurred by the close of business on November 17, 2010 (the “Termination Date”); provided, however, that if the Closing shall not have occurred on or before the Termination Date due to a material
breach of any representations, warranties, covenants or agreements contained in this Agreement by Biovest or the Agent or the Lenders, then the breaching party may not terminate this Agreement pursuant to this Section 14(d)(i); and provided,
further, that Biovest shall have the right to extend the Termination Date for a period not to exceed forty-five (45) days in the aggregate; 
 (ii)      by mutual written consent of Biovest, the Agent and the Lenders; 
 (iii)      by the Agent, if any condition to the obligations of the Lenders set forth in Section 14(e) or (g) shall have become incapable of fulfillment, other than
as a result of a breach by the Agent or the Lenders of any covenant or agreement contained in this Agreement, and such condition is not waived by the Agent and the Lenders; 

(iv)      by Biovest, if any condition to the obligations of Biovest set forth in
Section 14(f) or (g) shall have become incapable of fulfillment, other than as a result of a breach by Biovest of any covenant or agreement contained in this Agreement, and such condition is not waived by Biovest; 

(v)      by the Agent and the Lenders, if there shall be a material breach by Biovest of
any representation, warranty, covenant or agreement contained in this Agreement which would result in a failure of a condition set forth in Section 14(e) or (g) and which breach has not been cured by the earlier of (i) ten
(10) Business Days after the giving of written notice by the Agent to Biovest of such breach and (ii) the Termination Date; 
 (vi)      by Biovest, if there shall be a material breach by the Agent or the Lenders of any representation, warranty, covenant or agreement contained in this Agreement which
would result in a failure of a condition set forth in Section 14(f) or (g) and which breach has not been cured by the earlier of (i) ten (10) Business Days after the giving of written notice by Biovest to the Agent of such breach
and (ii) the Termination Date; or 
 (vii)      by Biovest or the Agent and
the Lenders, if there shall be in effect a Final Order of a Governmental Authority of competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated by this Agreement, it being agreed that
the parties hereto shall promptly appeal any adverse determination which is not non-appealable (and pursue such appeal with reasonable diligence). 

  
 20 

 (e)      Conditions Precedent to
Obligations of the Lenders.  The obligation of the Lenders to consummate the transactions contemplated by this Agreement is subject to the fulfillment, on or prior to the Closing Date, of each of the following conditions (any or all of
which may be waived by the Lenders in whole or in part to the extent permitted by applicable law): 

(i)      the representations and warranties of Biovest contained in this Agreement
(x) that are not qualified by materiality or Material Adverse Effect shall be true and correct in all respects on and as of the Closing, except to the extent expressly made as of an earlier date, in which case as of such earlier date, and
except to the extent that the failure of such representations and warranties to be true and correct would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and (y) that are qualified by materiality
or Material Adverse Effect shall be true and correct in all respects on and as of the Closing (disregarding any materiality or Material Adverse Effect qualifier contained therein), except to the extent expressly made as of an earlier date, in which
case as of such earlier date, and except to the extent that the failure of such representations and warranties to be true and correct would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; 

(ii)      Biovest shall have performed and complied in all material respects with all
obligations and agreements required in this Agreement to be performed or complied with by it prior to the Closing Date; and 
 (iii)      Biovest shall have delivered, or caused to be delivered, to the Agent all of the items set forth in Section 14(b). 

(f)      Conditions Precedent to Obligation of Biovest.  The obligations
of Biovest to consummate the transactions contemplated by this Agreement are subject to the fulfillment, on or prior to the Closing Date, of each of the following conditions (any or all of which may be waived by Biovest in whole or in part to the
extent permitted by applicable law): 
 (i)      the representations and
warranties of the Lenders contained in this Agreement (x) that are not qualified by materiality shall be true and correct in all respects on and as of the Closing, except to the extent expressly made as of an earlier date, in which case as of
such earlier date, and except to the extent that the failure of such representations and warranties to be true and correct would not reasonably be expected to have, individually or in the aggregate, a material adverse change and (y) that are
qualified by materiality shall be true and correct in all respects on and as of the Closing (disregarding any materiality qualifier contained therein), except to the extent expressly made as of an earlier date, in which case as of such earlier date,
and except to the extent that the failure of such representations and warranties to be true and correct would not reasonably be expected to have, individually or in the aggregate, a material adverse change; 

(ii)      the Lenders shall have performed and complied in all material respects with all
obligations and agreements required by this Agreement to be performed or complied with by the Lenders on or prior to the Closing Date; and 

  
 21 

 (iii)      the Agent and the Lenders, as
applicable, shall have delivered to Biovest all of the items set forth in Section 14(c). 

(g)      Conditions Precedent to Obligations of Biovest and the
Lenders.  The respective obligations of Biovest and the Lenders to consummate the transactions herein are subject to the fulfillment, on or prior to the Closing Date, of each of the following conditions (any or all of which may be
waived by Biovest and the Lenders in whole or in part to the extent permitted by applicable law): 

(i)      there shall not be in effect any Final Order by a Governmental Authority of
competent jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated by this Agreement; 
 (ii)      the Confirmation Order shall have become a Final Order; 
 (iii)      the closing shall have occurred under the Accentia Security Agreement; and 

(iv)      the Effective Date under the Confirmed Plan shall have occurred. 

(h)      Frustration of Closing Conditions.  No party may rely on the
failure of any condition set forth in Section 14(e), (f) or (g), as the case may be, if such failure was caused by such party’s failure to comply with any provision of this Agreement. 

15.      Further Assurances.  At any time and from time to time, upon the
written request of the Agent and at the sole expense of Biovest, Biovest shall promptly and duly execute and deliver any and all such further instruments and documents and take such further action as the Agent may reasonably request (a) to
obtain the full benefits of this Agreement and the Ancillary Agreements, (b) to protect, preserve, perfect and maintain the Agent’s rights in the Collateral and under this Agreement or any Ancillary Agreement, and/or (c) to enable the
Agent to exercise all or any of the rights and powers granted herein or in any Ancillary Agreement. 

16.      Representations, Warranties and Covenants of Lenders.  Each
Lender, severally and not jointly, hereby represents, warrants and covenants to Biovest as follows: 

(a)      Requisite Power and Authority.  Such Lender has all necessary
power and authority under all applicable provisions of law to execute and deliver this Agreement and the Ancillary Agreements and to carry out their provisions. All corporate action on such Lender’s part required for the lawful execution and
delivery of this Agreement and the Ancillary Agreements has been or will be effectively taken prior to the Closing Date. Upon their execution and delivery, this Agreement and the Ancillary Agreements shall be valid and binding obligations of such
Lender, enforceable in accordance with their terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, and (ii) as
limited by general principles of equity that restrict the availability of equitable and legal remedies. 

(b)      Investment Representations.  Such Lender understands that the
BVTI Term Notes, the Closing Shares and the Conversion Shares are being offered and sold pursuant 

  
 22 

 
to an exemption from registration contained in Section 1145(a) of the Bankruptcy Code and the Securities Act based in part upon such Lender’s representations contained in this
Agreement, including, without limitation, that such Lender is an “accredited investor” within the meaning of Regulation D under the Securities Act. Such Lender has received or has had full access to all the information it considers
necessary or appropriate to make an informed investment decision with respect to the Closing Shares and the BVTI Term Notes to be issued to it under this Agreement. 

(c)      Lender Bears Economic Risk.  Such Lender has substantial
experience in evaluating and investing in private placement transactions of securities in companies similar to Biovest so that it is capable of evaluating the merits and risks of its investment in Biovest and has the capacity to protect its own
interests. Such Lender must bear the economic risk of this investment until the BVTI Term Notes and the Closing Shares are sold pursuant to (i) an effective registration statement under the Securities Act, or (ii) an exemption from
registration is available, and subject to the terms of the Closing Shares Lock-Up Agreement. 

(d)      Investment for Own Account.  The BVTI Term Notes and the Closing
Shares are being issued to such Lender for its own account for investment only, and not as a nominee or agent and not with a view towards or for resale in connection with their distribution. 

(e)      Lender Can Protect Its Interest.  Such Lender represents that by
reason of its, or of its management’s, business and financial experience, such Lender has the capacity to evaluate the merits and risks of its investment in the BVTI Term Notes and the Closing Shares and to protect its own interests in
connection with the transactions contemplated in this Agreement and the Ancillary Agreements. Further, such Lender is aware of no publication of any advertisement in connection with the transactions contemplated in this Agreement or the Ancillary
Agreements. 
 (f)      Accredited Investor.  Such Lender
represents that it is an accredited investor within the meaning of Regulation D under the Securities Act. 

(g)      Patriot Act.  Such Lender certifies that, to the best of such
Lender’s knowledge, such Lender has not been designated, and is not owned or controlled, by a “suspected terrorist” as defined in Executive Order 13224. Such Lender seeks to comply with all applicable laws concerning money laundering
and related activities. In furtherance of those efforts, such Lender hereby represents, warrants and covenants that: (i) none of the cash or property that such Lender will use to make the BVTI Term Loans has been or shall be derived from, or
related to, any activity that is deemed criminal under United States law; and (ii) no disbursement by such Lender to Biovest, to the extent within such Lender’s control, shall cause such Lender to be in violation of the United States Bank
Secrecy Act, the United States International Money Laundering Control Act of 1986 or the United States International Money Laundering Abatement and Anti-Terrorist Financing Act of 2001. Such Lender shall promptly notify Biovest if any of these
representations ceases to be true and accurate regarding such Lender. Such Lender agrees to provide Biovest any additional information regarding such Lender that Biovest deems necessary or convenient to ensure compliance with all applicable law
concerning money laundering and similar activities. Such Lender understands and agrees that if at any time it is discovered that any of the foregoing representations are incorrect, or if otherwise required by applicable law or regulation related to
money laundering or similar activities, such 

  
 23 

 
Lender may undertake appropriate actions to ensure compliance with applicable law or regulation, including but not limited to segregation and/or redemption of such Lender’s investment in
Biovest. Such Lender further understands that Biovest may release information about such Lender and, if applicable, any underlying beneficial owners, to proper authorities if Biovest, in its sole discretion, determines that it is in the best
interests of Biovest in light of relevant rules and regulations under the laws set forth in subsection (ii) above. 
 (h)      Limitation on Acquisition of Stock.  Notwithstanding anything to the contrary contained in this Agreement, any Ancillary Agreement, or any document,
instrument or agreement entered into in connection with any other transaction entered into by and between such Lender and Biovest (and/or Affiliates of Biovest), such Lender (and/or Subsidiaries or Affiliates of such Lender) shall not acquire stock
in Biovest (including, without limitation, pursuant to a contract to purchase, by exercising an option or warrant, by converting any other security or instrument, by acquiring or exercising any other right to acquire shares of stock or other
security convertible into shares of stock in Biovest, or otherwise, and such options, warrants, conversion or other rights shall not be exercisable) to the extent such stock acquisition would cause any interest (including any original issue
discount) payable by Biovest to a Non-U.S. Lender not to qualify as portfolio interest, within the meaning of Section 871(h)(2) or Section 881(c)(2) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) by
reason of Section 87l(h)(3) or Section 88l(c)(3)(B) of the Code, as applicable, taking into account the constructive ownership rules under Section 871(h)(3)(C) of the Code (the “Stock Acquisition Limitation”).

 (i)      No Net Short Position.  From and after the date of
this Agreement, such Lender agrees that it shall not, either individually or collectively, maintain a Net Short Position. “Net Short Position” shall mean that the aggregate number of shares of Biovest Common Stock held in a short
position by such Lender exceeds the number of shares of Biovest Common Stock then owned by such Lender. 

(j)      Ancillary Agreements and Other Closing Documents.  The Agent and
the Lenders acknowledge and agree that, as a condition to the Closing, the closing under the Accentia Security Agreement shall have occurred and the Agent and the Lenders, as the case may be, shall have executed and delivered each of the Ancillary
Agreements and other documents listed in Section 14(c). 

17.      Confidentiality.  Except in connection with the Bankruptcy Cases,
each Lender covenants and agrees with Biovest that such Lender will not disclose, and will not include in any public announcement, Biovest’s name, unless expressly agreed to by Biovest or unless and until such disclosure is required by law or
applicable regulation, and then only to the extent of such requirement. Notwithstanding the foregoing, (i) such Lender shall be permitted to discuss, distribute or otherwise transfer any non-public information of Biovest in such Lender’s
possession now or in the future to (x) its employees, agents, counsel, professional consultants and accountants who, in each such case, have a specific need to know such information, and (y) potential or actual (A) direct or indirect
investors in such Lender and (B) assignees or transferees of all or a portion of the Obligations, to the extent that such investor or assignee or transferee enters into a confidentiality agreement for such benefit of Biovest in such form as may
be necessary to address Biovest’s Regulation FD requirements; (ii) such Lender (and each 

  
 24 

 
employee, representative, or other agent of such Lender) may disclose to any and all Persons, without limitation of any kind, the tax treatment and any facts that may be relevant to the tax
structure of the transactions contemplated by this Agreement and the Ancillary Agreements and the agreements referred to therein; provided, however, that no Lender (and no employee, representative or other agent thereof) shall disclose
pursuant to this clause (ii) any other information that is not relevant to understanding the tax treatment or tax structure of such transactions (including the identity of any party or any information that could lead another to determine the
identity of any party); and (iii) the Agent or any Affiliate thereof shall be entitled to post on its website a summary of the transactions contemplated by this Agreement, including Biovest’s name. 

18.      Power of Attorney.  Biovest hereby appoints the Agent, or any other Person whom
the Agent may designate as Biovest’s attorney, with power to: (a)(i) execute any security related documentation on Biovest’s behalf and to supply any omitted information and correct patent errors in any documents executed by Biovest or on
Biovest’s behalf; (ii) file financing statements and other evidence of Liens granted hereunder against Biovest covering the Collateral (and, in connection with the filing of any such financing statements, describe the Collateral as
“all assets and all personal property, whether now owned and/or hereafter acquired” (or any substantially similar variation thereof)); (iii) sign Biovest’s name on any invoice or bill of lading relating to any Accounts, drafts
against Account Debtors, schedules and assignments of Accounts, notices of assignment, financing statements and other evidence of the Agent’s Liens granted hereunder and other public records, verifications of Account and notices to or from
Account Debtors; (iv) in the case of any Intellectual Property, execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as the Agent may request to evidence the Agent’s security interest in such
Intellectual Property and the goodwill and general intangibles of Biovest relating thereto or represented thereby; and (v) do all other things the Agent deems necessary to carry out the terms of Section 6 of this Agreement; and
(b) upon the occurrence and during the continuance of an Event of Default (i) endorse Biovest’s name on any checks, notes, acceptances, money orders, drafts or other forms of payment or security that may come into the Agent’s
possession; (ii) verify the validity, amount or any other matter relating to any Account by mail, telephone, telegraph or otherwise with Account Debtors; (iii) do all other things necessary to carry out this Agreement, any Ancillary
Agreement and all related documents; and (iv) notify the post office authorities to change the address for delivery of Biovest’s mail to an address designated by the Agent, and to receive, open and dispose of all mail addressed to Biovest.
Biovest hereby ratifies and approves all acts of the attorney. Neither the Agent nor the attorney will be liable for any acts or omissions or for any error of judgment or mistake of fact or law, except for gross negligence or willful misconduct.
This power, being coupled with an interest, is irrevocable so long as the Agent has a security interest and until the Obligations have been fully satisfied. 
 19.      Termination of Lien.  The Liens and rights granted to the Agent hereunder and in any Ancillary Agreements, and the financing statements filed in
connection herewith or therewith, shall continue in full force and effect until all of the Obligations have been indefeasibly paid or performed in full. The Agent shall not be required to send termination statements or other evidence of the release
of the Liens granted hereunder to Biovest, or to file them with any filing office, unless and until this Agreement and the Ancillary Agreements shall 

  
 25 

 
have been terminated in accordance with their terms and all Obligations indefeasibly paid in full in immediately available funds. 

20.      Events of Default.  The occurrence of any of the following shall
constitute an “Event of Default”: 
 (a)      failure to make
payment of any principal, interest, fees, costs, charges, expenses, or other sums payable from time to time hereunder, under the BVTI Term Notes, under Section 5(b) of this Agreement, if any, or under any of the Ancillary Agreements when
required hereunder or thereunder, and, in any such case, such failure shall continue for (i) in the case of a payment of scheduled principal or interest, a period of five (5) Business Days following the date upon which any such payment was
due, (ii) in the case of payments due under Section 5(b), if any, that are not paid when due on eight (8) occasions, or (iii) in the case of any other amount payable, a period of five (5) Business Days following the date of
Biovest’s written receipt from the Agent of a written notice identifying the amount due and providing reasonable supporting details; 
 (b)      Biovest shall (i) apply for, consent to or suffer to exist the appointment of or the taking of possession by, a receiver, custodian, trustee or liquidator of
itself or of all or a substantial part of its property, (ii) make a general assignment for the benefit of creditors, (iii) commence a voluntary case under the federal bankruptcy laws (as now or hereafter in effect), (iv) be
adjudicated bankrupt or insolvent, (v) file a petition seeking to take advantage of any other law providing for the relief of debtors, (vi) acquiesce to without challenge within ten (10) days of the filing thereof, or fail to have
dismissed within forty-five (45) days, any petition filed against it in any involuntary case under such bankruptcy laws, or (vii) take any action for the purpose of effecting any of the foregoing; 

(c)      Biovest shall cease operation of its present business; or 

(d)      Biovest directly or indirectly sells, assigns, transfers, conveys, or suffers or
permits to occur any sale, assignment, transfer or conveyance of all or substantially all of its assets, except as permitted herein. 
 21.      Remedies.  Following the occurrence of an Event of Default that is continuing, the Agent shall have the right to demand repayment in full of all
Obligations, whether or not otherwise due. Until all Obligations have been fully and indefeasibly satisfied, the Agent shall retain its Lien in all Collateral. The Agent shall have, in addition to all other rights provided herein and in each
Ancillary Agreement, the rights and remedies of a secured party under the UCC, and under other applicable law, all other legal and equitable rights to which the Agent may be entitled, including the right to take immediate possession of the
Collateral, to require Biovest to assemble the Collateral, at Biovest’s expense, and to make it available to the Agent at a place designated by the Agent which is reasonably convenient to both parties and to enter any of the premises of Biovest
or wherever the Collateral shall be located, with or without force or process of law, and to keep and store the same on said premises until sold (and if said premises be the property of Biovest, Biovest agrees not to charge the Agent or any Lender
for storage thereof), and the right to apply for the appointment of a receiver for Biovest’s property. Further, the Agent may, at any time or times after the occurrence of an Event of Default that is continuing, 

  
 26 

 
sell and deliver all Collateral held by or for the Agent at public or private sale for cash, upon credit or otherwise, at such prices and upon such terms as the Agent, in its sole discretion,
deems advisable or the Agent may otherwise recover upon the Collateral in any commercially reasonable manner. The requirement of reasonable notice shall be met if such notice is mailed postage prepaid to Biovest at Biovest’s address as shown in
Section 30, at least ten (10) days before the time of the event of which notice is being given. The Agent may be the purchaser at any sale, if it is public. In connection with the exercise of the foregoing remedies, and not without
limitations of any remedies with respect to Intellectual Property Collateral, the Agent may exercise the rights and license granted under Section 6(c) hereof. The proceeds of sale shall be applied first to all costs and expenses of sale,
including reasonable attorneys’ fees, and second to the payment (in whatever order the Agent elects) of all Obligations. After the indefeasible payment and satisfaction in full of all of the Obligations, and after the payment by the Agent of
any other amount required by any provision of law, including Section 9-608(a)(1) of the UCC (but only after the Agent has received what the Agent considers reasonable proof of a subordinate party’s security interest), the surplus, if any,
shall be paid to Biovest or its representatives or to whosoever may be lawfully entitled to receive the same, or as a court of competent jurisdiction may direct. Biovest shall remain liable to the Creditor Parties for any deficiency. The parties
hereto each hereby agree that the exercise by any party hereto of any right granted to it or the exercise by any party hereto of any remedy available to it (including, without limitation, the issuance of a notice of redemption, a borrowing request
and/or a notice of default), in each case, hereunder or under any Ancillary Agreement shall not constitute confidential information and no party shall have any duty to the other party to maintain such information as confidential, except for the
portions of such publicly filed documents that are subject to a confidential treatment request made by Biovest to the SEC. 

22.      Waivers.  To the full extent permitted by applicable law, Biovest hereby waives
(a) presentment, demand and protest, and notice of presentment, dishonor, intent to accelerate, acceleration, protest, default, nonpayment, maturity, release, compromise, settlement, extension or renewal of any or all of this Agreement and the
Ancillary Agreements or any other notes, commercial paper, Accounts, contracts, Documents, Instruments, Chattel Paper and guaranties at any time held by the Agent on which Biovest may in any way be liable, and hereby ratifies and confirms whatever
the Agent may do in this regard; (b) all rights to notice and a hearing prior to the Agent’s taking possession or control of, or to the Agent’s replevy, attachment or levy upon, any Collateral or any bond or security that might be
required by any court prior to allowing the Agent to exercise any of its remedies; and (c) the benefit of all valuation, appraisal and exemption laws. Biovest acknowledges that it has been advised by counsel of its choices and decisions with
respect to this Agreement, the Ancillary Agreements and the transactions evidenced hereby and thereby. 

23.      Expenses.  Biovest shall pay all of the Agent’s out-of-pocket costs and
expenses, including reasonable fees and disbursements of outside counsel and appraisers, in connection with the prosecution or defense of any action, contest, dispute, suit or proceeding concerning any matter in any way arising out of, related to or
connected with this Agreement or any Ancillary Agreement. Biovest shall also pay all of the Agent’s reasonable fees, charges, out-of-pocket costs and expenses, including fees and disbursements of counsel and appraisers, in connection with
(a) the preparation, execution and delivery of any waiver, any amendment thereto or consent proposed or executed in connection with the transactions contemplated by this 

  
 27 

 
Agreement or the Ancillary Agreements, (b) the Agent’s obtaining performance of the Obligations under this Agreement and any Ancillary Agreements, including, but not limited to, the
enforcement or defense of the Agent’s security interests, assignments of rights and Liens hereunder as valid perfected security interests, (c) any attempt to inspect, verify, protect, collect, sell, liquidate or otherwise dispose of any
Collateral, (d) any appraisals or re-appraisals of any property (real or personal) pledged to the Agent by Biovest as Collateral for, or any other Person as security for, the Obligations hereunder, and (e) any consultations in connection
with any of the foregoing. Biovest shall also pay each Creditor Party the customary bank charges for any bank services (including wire transfers) performed or caused to be performed by it at its request or in connection with Biovest’s loan
account with such Creditor Party. All such costs and expenses together with all filing, recording and search fees, taxes and interest payable by Biovest to the Creditor Parties shall be payable on demand and shall be secured by the Collateral. If
any tax by any Governmental Authority is or may be imposed on or as a result of any transaction between Biovest, on the one hand, and Creditor Party on the other hand, which such Creditor Party is or may be required to withhold or pay, Biovest
hereby indemnifies and holds such Creditor Party harmless in respect of such taxes, and Biovest will repay to such Creditor Party the amount of any such taxes which shall be charged to Biovest’s account; and until Biovest shall furnish such
Creditor Party with indemnity therefor (or supply such Creditor Party with evidence satisfactory to it that due provision for the payment thereof has been made), such Creditor Party may hold without interest any balance standing to Biovest’s
credit and the Agent shall retain its Liens in any and all Collateral. 

24.      Assignment; Register. 

(a)      Each Lender may assign any or all of the Obligations to any Person and, subject to
acceptance and recordation thereof by the Agent pursuant to Section 24(b) and receipt by the Agent of a copy of the agreement or instrument pursuant to which such assignment is made (each such agreement or instrument, an “Assignment
Agreement”), any such assignee shall succeed to all of such Lender’s rights with respect thereto; provided that no Lender shall be permitted to effect any such assignment to a direct competitor of Biovest unless an Event of Default has
occurred and is continuing and such Lender has given Biovest no less than fifteen (15) Business Days prior notice of such assignment. Each Lender may from time to time sell or otherwise grant participations in any of the Obligations and the
holder of any such participation shall, subject to the terms of any agreement between such Lender and such holder, be entitled to the same benefits as such Lender with respect to any security for the Obligations in which such holder is a
participant. Biovest agrees that each such holder may exercise any and all rights of banker’s lien, set-off and counterclaim with respect to its participation in the Obligations as fully as though Biovest were directly indebted to such holder
in the amount of such participation. Biovest may not assign any of its rights or obligations hereunder without the prior written consent of the Agent. All of the terms, conditions, promises, covenants, provisions and warranties of this Agreement
shall inure to the benefit of each of the undersigned, and shall bind the representatives, successors and permitted assigns of Biovest and the Creditor Parties. 

(b)      The Agent shall maintain, or cause to be maintained, for this purpose only as
agent for each Lender, (i) a copy of each Assignment Agreement delivered to it and (ii) a book entry system, within the meaning of U.S. Treasury Regulation Sections 5f.103-1(c) and 1.871-14(c) (the “Register”), in which it
will register the name and address of each Lender and the 

  
 28 

 
name and address of each assignee of each Lender under this Agreement, and the principal amount of, and stated interest on, the BVTI Term Loans owing to each such Lender and assignee pursuant to
the terms hereof and each Assignment Agreement. The right, title and interest of the Lenders and their assignees in and to such BVTI Term Loans shall be transferable only upon notation of such transfer in the Register, and no assignment thereof
shall be effective until recorded therein. Biovest and each Creditor Party shall treat each Person whose name is recorded in the Register as a Lender pursuant to the terms hereof as a Lender and owner of an interest in the Obligations hereunder for
all purposes of this Agreement, notwithstanding notice to the contrary or any notation of ownership or other writing or any BVTI Term Note. The Register shall be available for inspection by Biovest or Lender, at any reasonable time and from time to
time, upon reasonable prior notice. 
 25.      No Waiver; Cumulative
Remedies.  Failure by any Creditor Party to exercise any right, remedy or option under this Agreement, any Ancillary Agreement or any supplement hereto or thereto or any other agreement between or among Biovest and such Creditor Party,
will not operate as a waiver; no waiver by any Creditor Party will be effective unless it is in writing and then only to the extent specifically stated. The Creditor Parties’ rights and remedies under this Agreement and the Ancillary Agreements
will be cumulative and not exclusive of any other right or remedy which any of the Creditor Parties may have. 

26.      Application of Payments.  Except as otherwise provided in this Agreement or in
any Ancillary Agreement, Biovest irrevocably waives the right to direct the application of any and all payments at any time or times hereafter received by the Agent from or on Biovest’s behalf and Biovest hereby irrevocably agrees that the
Agent shall have the continuing exclusive right to apply and reapply any and all payments received at any time or times hereafter against the Obligations hereunder in such manner as the Agent may reasonably deem advisable notwithstanding any entry
by the Agent upon any of the Agent’s books and records. 

27.      Indemnity.  Biovest hereby indemnifies and holds each Creditor Party, and its
respective affiliates, employees, attorneys and agents (each, an “Indemnified Person”), harmless from and against any and all suits, actions, proceedings, claims, damages, losses, liabilities and expenses of any kind or nature
whatsoever (including reasonable attorneys’ fees and disbursements and other costs of investigation or defense, including those incurred upon any appeal) which may be instituted or asserted against or incurred by any such Indemnified Person as
the result of credit having been extended, suspended or terminated under this Agreement or any of the Ancillary Agreements or with respect to the execution, delivery, enforcement, performance and administration of, or in any other way arising out of
or relating to, this Agreement, the Ancillary Agreements or any other documents or transactions contemplated by or referred to herein or therein and any actions or failures to act with respect to any of the foregoing, except to the extent that any
such indemnified liability is finally determined by a court of competent jurisdiction to have resulted primarily from such Indemnified Person’s gross negligence, bad faith or willful misconduct. NO INDEMNIFIED PERSON SHALL BE RESPONSIBLE OR
LIABLE TO BIOVEST OR TO ANY OTHER PARTY OR TO ANY SUCCESSOR, ASSIGNEE OR THIRD PARTY BENEFICIARY OR ANY OTHER PERSON ASSERTING CLAIMS DERIVATIVELY THROUGH SUCH PARTY, FOR INDIRECT, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES WHICH MAY BE ALLEGED AS
A RESULT OF CREDIT HAVING BEEN EXTENDED, SUSPENDED OR 

  
 29 

 
TERMINATED UNDER THIS AGREEMENT OR ANY ANCILLARY AGREEMENT OR AS A RESULT OF ANY OTHER TRANSACTION CONTEMPLATED HEREUNDER OR THEREUNDER. 

28.      Revival.  Biovest further agrees that to the extent it makes a
payment or payments to any Creditor Party, which payment or payments or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside and/or required to be repaid to a trustee, receiver or any other party under
any bankruptcy act, state or federal law, common law or equitable cause, then, to the extent of such payment or repayment, the obligation or part thereof intended to be satisfied shall be revived and continued in full force and effect as if said
payment had not been made. 
 29.      Borrowing Agency Provisions.

 (a)      Biovest shall make payment upon the maturity of the Obligations by
acceleration or otherwise, and such obligation and liability shall in no way be affected by any extensions, renewals and forbearance granted by the Agent to Biovest, failure of the Agent to give Biovest notice of borrowing or any other notice, any
failure of the Agent to pursue to preserve its rights against Biovest, the release by the Agent of any Collateral now or thereafter acquired from Biovest, and such agreement by Biovest to pay upon any notice issued pursuant thereto is unconditional
and unaffected by prior recourse by the Agent to Biovest or any Collateral for Biovest’s Obligations or the lack thereof. 
 (b)      Biovest expressly waives any and all rights of subrogation, reimbursement, indemnity, exoneration, contribution or any other claim which Biovest may now or hereafter
have against any other Person directly or contingently liable for the Obligations, or against or with respect to any other’s property (including, without limitation, any property which is Collateral for the Obligations), arising from the
existence or performance of this Agreement, until all Obligations have been indefeasibly paid in full and this Agreement has been irrevocably terminated. 
 30.      Notices.  Any notice or request hereunder may be given to Biovest or the Agent and the Lenders at the respective addresses set forth below or as may
hereafter be specified in a notice designated as a change of address under this Section. Any notice or request hereunder shall be given by registered or certified mail, return receipt requested, hand delivery, overnight mail or facsimile
transmission (confirmed by mail). Notices and requests shall be, in the case of those by hand delivery, deemed to have been given when delivered to any officer of the party to whom it is addressed, in the case of those by registered or certified
mail or overnight mail, deemed to have been given three (3) Business Days after the date when deposited in the mail or with the overnight mail carrier, and, in the case of a facsimile transmission, when confirmed. 

Notices shall be provided as follows: 

  
 30 

					
		 	If to the Agent or the Lenders:  	 	LV Administrative Services, Inc.
		 		 	875 Third Avenue, 3rd Floor
		 		 	New York, New York 10022
		 		 	Attention: Portfolio Services
		 		 	Telephone:  (212) 541-5800
		 		 	Facsimile:    (212) 581-5037
			
		 	With a copy to:	 	Cole, Schotz, Meisel, Forman & Leonard, P.A.
		 		 	25 Main Street, Court Plaza North
		 		 	Hackensack, New Jersey 07601
		 		 	Attention: Stuart Komrower, Esq. & Marc P. Press, Esq.
		 		 	Telephone:  (201) 525-6331
		 		 	Facsimile:    (201) 678-6331
			
		 	If to Biovest:	 	Biovest International, Inc.
		 		 	324 South Hyde Park Avenue, Suite 350
		 		 	Tampa, Florida 33606
		 		 	Attention: David Moser, Secretary
		 		 	Telephone:  (813) 864-2554
		 		 	Facsimile:    (813) 258-6912
			
		 	With a copy to:	 	Stichter, Riedel, Blain & Prosser, P.A.
		 		 	110 East Madison Street, Suite 200
		 		 	Tampa, Florida 33602
		 		 	Attention: Charles A. Postler, Esq.
		 		 	Telephone:  (813) 229-0144
		 		 	Facsimile:    (813) 229-1811
		 		 	            and
		 		 	Foley & Lardner LLP
		 		 	100 North Tampa Street, Suite 2700
		 		 	Tampa, Florida 33602
		 		 	Attention: Curt P. Creely, Esq.
		 		 	Telephone:  (813) 229-2300
		 		 	Facsimile:    (813) 221-4210

 or such other address as may be designated in writing hereafter in accordance with this Section 30 by such Person. 

31.      Governing Law, Jurisdiction and Waiver of Jury Trial. 

 (a)      THIS AGREEMENT AND THE ANCILLARY AGREEMENTS SHALL BE GOVERNED BY AND
CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW. 

  
 31 

 (b)      BIOVEST HEREBY CONSENTS AND AGREES
THAT THE STATE AND/OR FEDERAL COURTS LOCATED IN THE COUNTY OF NEW YORK, STATE OF NEW YORK SHALL HAVE EXCLUSIVE JURISDICTION TO HEAR AND DETERMINE ANY CLAIMS OR DISPUTES BETWEEN BIOVEST, ON THE ONE HAND, AND ANY CREDITOR PARTY, ON THE OTHER HAND,
PERTAINING TO THIS AGREEMENT OR ANY OF THE ANCILLARY AGREEMENTS OR TO ANY MATTER ARISING OUT OF OR RELATED TO THIS AGREEMENT OR ANY OF THE ANCILLARY AGREEMENTS; PROVIDED, THAT EACH CREDITOR PARTY AND BIOVEST ACKNOWLEDGE THAT ANY APPEALS FROM
THOSE COURTS MAY HAVE TO BE HEARD BY A COURT LOCATED OUTSIDE OF THE COUNTY OF NEW YORK, STATE OF NEW YORK; AND FURTHER PROVIDED, THAT NOTHING IN THIS AGREEMENT SHALL BE DEEMED OR OPERATE TO PRECLUDE ANY CREDITOR PARTY FROM BRINGING
SUIT OR TAKING OTHER LEGAL ACTION IN ANY OTHER JURISDICTION TO COLLECT THE OBLIGATIONS, TO REALIZE ON THE COLLATERAL OR ANY OTHER SECURITY FOR THE OBLIGATIONS, OR TO ENFORCE A JUDGMENT OR OTHER COURT ORDER IN FAVOR OF ANY CREDITOR PARTY. BIOVEST
EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND BIOVEST HEREBY WAIVES ANY OBJECTION THAT IT MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON
CONVENIENS. BIOVEST HEREBY WAIVES PERSONAL SERVICE OF THE SUMMONS, COMPLAINT AND OTHER PROCESS ISSUED IN ANY SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINT AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL
ADDRESSED TO BIOVEST AT THE ADDRESS SET FORTH IN SECTION 30 AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER OF BIOVEST’S ACTUAL RECEIPT THEREOF OR THREE (3) DAYS AFTER DEPOSIT IN THE U.S. MAILS, PROPER POSTAGE PREPAID.

 (c)      THE PARTIES DESIRE THAT THEIR DISPUTES BE RESOLVED BY A JUDGE APPLYING
SUCH APPLICABLE LAWS. THEREFORE, TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF THE JUDICIAL SYSTEM AND/OR OF ARBITRATION, THE PARTIES HERETO WAIVE ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE,
WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE BETWEEN ANY CREDITOR PARTY AND/OR BIOVEST ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION WITH THIS AGREEMENT, ANY ANCILLARY AGREEMENT
OR THE TRANSACTIONS RELATED HERETO OR THERETO. 
 32.      Limitation of
Liability.  Biovest acknowledges and understands that in order to assure repayment of the Obligations hereunder the Creditor Parties may be required to exercise any and all of the Creditor Parties’ rights and remedies hereunder
and agrees that, except as limited by applicable law, neither the Creditor Parties nor any of their respective agents shall be liable for acts taken or omissions made in connection herewith or therewith except to the extent such acts or omissions
result from or constitute bad faith, gross negligence or willful misconduct of the Creditor Parties or any of the Creditor Parties’ agents. 

  
 32 

 33.      Entire Understanding; Maximum
Interest.  This Agreement and the Ancillary Agreements (together with any provisions of the Confirmed Plan relevant to the subject matter hereof) contain the entire understanding among Biovest, the Lenders and the Agent as to the
subject matter hereof and thereof and any promises, representations, warranties or guarantees not herein contained shall have no force and effect unless in writing, signed by Biovest and the Agent. Neither this Agreement, the Ancillary Agreements,
nor any portion or provisions thereof may be changed, modified, amended, waived, supplemented, discharged, cancelled or terminated orally or by any course of dealing, or in any manner other than by an agreement in writing, signed by the party to be
charged. Nothing contained in this Agreement, any Ancillary Agreement or in any document referred to herein or delivered in connection herewith shall be deemed to establish or require the payment of a rate of interest or other charges in excess of
the Maximum Legal Rate. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the Maximum Legal Rate, any payments in excess of such Maximum Legal Rate shall be credited against amounts owed by
Biovest to the Creditor Parties and thus refunded to Biovest. 

34.      Severability.  Wherever possible, each provision of this Agreement or the
Ancillary Agreements shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement or the Ancillary Agreements shall be prohibited by or invalid under applicable law such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions thereof. 
 35.      Survival.  The representations, warranties, covenants and agreements made herein shall survive any investigation made by any Creditor Party and the
Closing of the transactions contemplated hereby; provided, however, the representations and warranties that relate solely to a specific date by their express terms shall only be deemed to have been made as of such date and are hereby
represented and warranted to have been true and correct when made. All statements as to factual matters contained in any certificate or other instrument delivered by or on behalf of Biovest pursuant hereto in connection with the transactions
contemplated hereby shall be deemed to be representations and warranties by Biovest hereunder solely as of the date of such certificate or instrument. All indemnities set forth herein shall survive the execution, delivery and termination of this
Agreement and the Ancillary Agreements and the making and repaying of the Obligations. 

36.      Captions.  All captions are and shall be without substantive meaning or content
of any kind whatsoever. 
 37.      Counterparts; Signatures.  This Agreement may
be executed in one or more counterparts, each of which shall constitute an original and all of which taken together shall constitute one and the same agreement. Any signature delivered by a party via facsimile or electronic transmission shall be
deemed to be an original signature hereto. 
 38.      Construction.  The parties
acknowledge that each party and its counsel have reviewed this Agreement and that the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this
Agreement or any amendments, schedules or exhibits thereto. 

  
 33 

 39.      Publicity.  Biovest hereby
authorizes each Creditor Party to make appropriate announcements of the financial arrangement entered into by and among Biovest and each Creditor Party, including, without limitation, announcements which are commonly known as tombstones, in such
publications and to such selected parties as the Agent shall in its sole and absolute discretion deem appropriate, or as required by applicable law. 
 40.      Joinder.  It is understood and agreed that any Person that desires to become a party hereunder, or is required to execute a counterpart of this
Agreement after the date hereof pursuant to the requirements of this Agreement or any Ancillary Agreement, shall become a party hereunder by (a) executing a Joinder Agreement in form and substance satisfactory to the Agent, (b) delivering
supplements to such exhibits and annexes to this Agreement and the Ancillary Agreements as the Agent shall reasonably request and (c) taking all actions as specified in this Agreement as would have been taken by such party had it been an
original party to this Agreement, in each case with all documents required above to be delivered to the Agent and with all documents and actions required above to be taken to the reasonable satisfaction of the Agent. 

41.      Legends.  The BVTI Term Notes and the Closing Shares shall bear legends as
follows: 
 (a)      The BVTI Term Notes shall bear substantially the following legend:

 “THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF
(A) AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE OR SUCH COMMON STOCK UNDER SUCH SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR (B) AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS. THIS NOTE IS ISSUED IN REGISTERED FORM.
UNLESS THIS NOTE IS PRESENTED BY THE HOLDER (AS DEFINED BELOW) FOR REGISTRATION OF TRANSFER, EXCHANGE, CONVERSION OR PAYMENT, ANY TRANSFER, EXCHANGE OR OTHER USE SHALL BE VOID AND PAYMENT SHALL NOT BE MADE. TRANSFER OF ALL OR ANY PORTION OF THIS
NOTE IS PERMITTED SUBJECT TO THE PROVISIONS SET FORTH IN THE SECURITY AGREEMENT (AS DEFINED BELOW).” 

(b)      The Closing Shares shall bear a legend which shall be in substantially the following form until
the Closing Shares are covered by an effective registration statement filed with the SEC: 

  
 34 

 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THESE SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH
SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR (B) AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS.” 
 42.      Agency.  Each Lender has, pursuant to an Administrative and Collateral Agency Agreement, hereby designated and appointed the Agent as the
administrative and collateral agent of such Lender under this Agreement and the Ancillary Agreements. 
 [remainder of page
intentionally left blank] 

  
 35 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first written above. 
  

			
	BIOVEST INTERNATIONAL, INC.

			
		
	By:	 	     /s/ David
Moser

			
	Name:	 	David Moser

			
	Title:	 	Secretary
	
	LV ADMINISTRATIVE SERVICES, INC.

			
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory
	
	 PSOURCE STRUCTURED DEBT
 LIMITED By: PSource Capital Ltd, Its
 Investment
Consultant

			
		
	By:	 	     /s/ Charles
Lews

			
	Name:	 	Charles Lews

			
	Title:	 	Authorized Signatory
	
	VALENS U.S. SPV I, LLC

			
	By:	 	 Valens Capital Management, LLC,
 its investment manager

			
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory
	
	VALENS OFFSHORE SPV I, LTD.

			
	By:	 	 Valens Capital Management, LLC,
 its investment manager

			
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory
	
	VALENS OFFSHORE SPV II, CORP.

			
	By:	 	 Valens Capital Management, LLC,
 its investment manager

			
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory

  
 36 

			
	LAURUS MASTER FUND LTD.
	(In Liquidation)

			
		
	By:	 	     /s/ Russell
Smith

			
	Name:	 	Russell Smith

			
	Title:	 	 Joint Official Liquidator (with no
 personal liability)

	ERATO CORP.
	By:	 	

			
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory

  
 37 

 Annex A - Definitions 

“Accentia” means Accentia Biopharmaceuticals, Inc., a Florida corporation, and its successors and
assigns. 
 “Accentia Companies” means Accentia and its subsidiaries, other than Biovest,
Biovax, Inc., AutovaxID, Inc., Biolender, LLC and Biolender II, LLC. 
 “Accentia Limited
Guaranty” means the Limited Guaranty, dated the Closing Date, from Accentia in favor of the Agent, as it may be amended, modified or supplemented. 
 “Accentia Pledge Agreement” means the Stock Pledge Agreement, dated the Closing Date, by and between Accentia and the Agent with respect to the pledge in favor of the Agent of certain of
the shares of Biovest Common Stock held by Accentia, as it may be amended, modified or supplemented. 

“Accentia Royalty Termination Agreement” means the Royalty Termination Agreement, dated the Closing
Date, by and between Biovest and Accentia, and acknowledged by certain of the Prepetition Lenders and the Agent, providing for the termination of any and all rights granted to Accentia, prior to the Petition Date, to receive royalties from the
Biovest Biologic Products. 
 “Accentia Security Agreement” means the Term Loan and Security
Agreement, dated the Closing Date, by and among the Agent, the lenders party thereto and Accentia, as it may be amended, modified or supplemented. 
 “Accentia Subordination Agreement” means the Subordination Agreement, dated the Closing Date, by and between the Agent and Accentia, as it may be amended, modified or supplemented.

 “Accentia Term Notes” means the Secured Term Notes of Accentia, dated the Closing Date, in
an aggregate principal amount of $8,800,000 issued to the lenders party to the Accentia Security Agreement. 

“Account Debtor” means any Person who is or may be obligated with respect to, or on account of, an
Account. 
 “Accountants” has the meaning given to such term in Section 11(a). 

“Accounts” means all “accounts,” as such term is defined in the UCC, now owned or hereafter
acquired by any Person, including: (a) all accounts receivable, other receivables, book debts and other forms of obligations (other than forms of obligations evidenced by Chattel Paper or Instruments) (including any such obligations that may be
characterized as an account or contract right under the UCC); (b) all of such Person’s rights in, to and under all purchase orders or receipts for goods or services; (c) all of such Person’s rights to any Goods represented by any
of the foregoing (including unpaid sellers’ rights of rescission, replevin, reclamation and stoppage in transit and rights to returned, reclaimed or repossessed goods); (d) all rights to payment due to such Person for Goods or other
property sold, leased, licensed, assigned or otherwise disposed of, for a policy of insurance issued or to be issued, for a secondary obligation 

  
 1 

 
incurred or to be incurred, for energy provided or to be provided, for the use or hire of a vessel under a charter or other contract, arising out of the use of a credit card or charge card, or
for services rendered or to be rendered by such Person or in connection with any other transaction (whether or not yet earned by performance on the part of such Person); and (e) all collateral security of any kind given by any Account Debtor or
any other Person with respect to any of the foregoing. 
 “Administrative and Collateral Agency
Agreement” means the Administrative and Collateral Agency Agreement among the Agent, the Lenders and such other parties thereto from time to time, as amended, modified, supplemented and restated from time to time. 

“Affiliate” means, with respect to any Person, (a) any other Person (other than a Subsidiary)
which, directly or indirectly, is in control of, is controlled by, or is under common control with such Person, (b) any other Person that, directly or indirectly, owns or controls, whether beneficially, or as trustee, guardian or other
fiduciary, twenty-five percent (25.0%) or more of the Equity Interests having ordinary voting power in the election of directors of such Person, (c) any other Person who is a director, officer, joint venturer or partner (i) of such
Person, (ii) of any Subsidiary of such Person or (iii) of any Person described in clause (a) above or (d) in the case of Biovest, the immediate family members, spouses and lineal descendants of individuals who are Affiliates of
Biovest. For the purposes of this definition, control of a Person shall mean the power (direct or indirect) to direct or cause the direction of the management and policies of such Person whether by contract or otherwise; provided
however, that the term “Affiliate” shall specifically exclude any Creditor Party. 

“Agent” has the meaning given such term in the preamble. 

“Agreement” has the meaning given such term in the preamble. 

“Analytica” means Analytica International, Inc., a Florida corporation, and its successors and assigns.

 “Analytica Guaranty” means the Guaranty, dated the Closing Date, from Analytica in favor of
the Agent, as it may be amended, modified or supplemented. 
 “Analytica Security Agreement”
means the Security Agreement, dated the Closing Date, from Analytica in favor of the Agent, as it may be amended, modified or supplemented. 
 “Ancillary Agreements” means the BVTI Term Notes, the Accentia Limited Guaranty, the Security Documents, the Closing Shares Lock-Up Agreement, and all other agreements, instruments,
documents, mortgages, pledges, powers of attorney, consents, assignments, contracts, notices, security agreements, trust agreements and guarantees whether heretofore or concurrently executed by or on behalf of Biovest, any of its Affiliates or any
other Person or delivered to any of the Creditor Parties, relating to this Agreement or to the transactions contemplated by this Agreement, as each of the same may be amended, supplemented, restated or otherwise modified from time to time.

 “Assignment Agreement” has the meaning given such term in Section 24(a). 

  
 2 

 “AutovaxID Royalty Termination
Agreement” means the Termination Agreement, dated the Closing Date, by and between Biovest, on the one hand, and the Prepetition Lenders and the Agent, on the other hand, providing for the termination of any and all rights of the
Prepetition Lenders and the Agent to receive royalties for the sale of the automated cell and biologic production instrument known as AutovaxIDTM manufactured by Biovest, as it may be amended, modified or supplemented. 

“Bankruptcy Cases” has the meaning given such term in the Background. 

“Bankruptcy Code” has the meaning given such term in the Background. 

“Bankruptcy Court” has the meaning given such term in the Background. 

“BiovaxID®” means the patient-specific anti-cancer vaccine being developed by Biovest that is
focused primarily on treating follicular non-Hodgkins lymphoma. 
 “Biovest” has the meaning
given such term in the preamble. 
 “Biovest Amendments to Organizational Documents” means the
amendments to, or the amendments and restatements of, Biovest’s Certificate of Incorporation and Bylaws, including with respect to the right of the Agent to appoint under certain circumstances one-third (1/3) of the members of the Board of
Directors of Biovest. 
 “Biovest Bankruptcy Cases” means, collectively, the jointly
administered cases previously pending before the Bankruptcy Court under Chapter 11 of the Bankruptcy Code, which cases were commenced by Biovest, Biovax, Inc., AutovaxID, Inc., Biolender, LLC and Biolender II, LLC on the Petition Date, bearing Case
Nos. 8:08-bk-17796-KRM (Biovest International, Inc.), 8:08-bk-17803-KRM (Biovax, Inc.), 8:08-bk-17804-KRM (AutovaxID, Inc.), 8:08-bk-17805-KRM (Biolender, LLC), and 8:08-bk-17806-KRM (Biolender II, LLC). Pursuant to the Confirmation Order, the
Biovest Bankruptcy Cases have been substantively consolidated under Case No. 8:08-bk-17796-KRM. 

“Biovest Biologic Products” means all biopharmaceutical products, including but not limited to
monoclonal antibodies, peptides, infectious disease and cancer vaccines, including but not limited to BiovaxID®, autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell carcinoma, cell-based therapies, stem cells, cytokines,
and viruses produced by mouse-human heterohybridoma cell culture techniques, which are currently owned, licensed or being developed by Biovest or its Affiliates or which may be subsequently acquired or developed by Biovest or its Affiliates during
the term of the Biovest Contingent Payment Agreement. Notwithstanding the foregoing, Biovest Biologic Products shall not include (i) any vaccines for respiratory viruses, such as influenza, (ii) any biopharmaceutical products produced
under contract for third parties, (iii) any biopharmaceutical products being developed by Biovest or its Affiliates for third parties or (iv) any products owned, licensed, or developed by the Accentia Companies; provided that in the cases
of clauses (i), (ii) and (iii), no such vaccine for a respiratory virus or biopharmaceutical product shall be based upon or related to the BiovaxID vaccine, Biovest’s Intellectual Property (as of the date hereof) or shall be based on an
autologous production process or shall be produced using mouse-human heterohybridoma cell culture techniques. 

  
 3 

 “Biovest Common Stock” means the common stock, par value
$.01 per share, of Biovest. 
 “Biovest Contingent Payment Agreement” means the Contingent
Payment Agreements, dated the Closing Date, by and between Biovest and Erato Corp., Valens Offshore SPV I, Ltd., Valens Offshore SPV II, Corp., Valens U.S. SPV I, LLC, and PSource Structured Debt Limited, as each agreement may be amended, modified
or supplemented. 
 “Biovest Royalty” has the meaning given such term in the Background.

 “Biovest Warrants” has the meaning given such term in the Background. 

“Books and Records” means all books, records, board minutes, contracts, licenses, insurance policies,
environmental audits, business plans, files, computer files, computer discs and other data and software storage and media devices, accounting books and records, financial statements (actual and pro forma), filings with Governmental Authorities and
any and all records and instruments relating to the Collateral or otherwise necessary or helpful in the collection thereof or the realization thereupon. 
 “Business Day” means a day that is not a Saturday, a Sunday or other day on which banks are required or permitted to be closed in the State of New York. 

“BVTI Term Loans” means, collectively, Indebtedness of Biovest evidenced by the BVTI Term Notes and all
other extensions of credit to Biovest under this Agreement and under any Ancillary Agreement. 
 “BVTI
Term Notes” has the meaning given such term in Section 2(a)(i). 
 “Capital
Lease” means, with respect to any Person, any lease of, or other arrangement conveying the right to use, any property (whether real, personal or mixed) by such Person as lessee that has been or should be accounted for as a capital lease on
a balance sheet of such Person prepared in accordance with GAAP. 
 “Capitalized Lease
Obligations” means, at any time, with respect to any Capital Lease, any lease entered into as part of any sale/leaseback transaction of any Person or any synthetic lease, the amount of all obligations of such Person that is (or that would
be, if such synthetic lease or other lease were accounted for as a Capital Lease) capitalized on a balance sheet of such Person prepared in accordance with GAAP. 

“Charter” means the Certificate of Incorporation of Biovest as it may be amended or amended and
restated. 
 “Chattel Paper” means all “chattel paper,” as such term is defined in
the UCC, including electronic chattel paper, now owned or hereafter acquired by any Person. 

“Closing” has the meaning given such term in Section 14(a). 

“Closing Date” has the meaning given such term in Section 14(a). 

  
 4 

 “Closing Shares” means the shares of
Biovest Common Stock to be issued to the Lenders at the Closing as provided in Section 2(b). 

“Closing Shares Lock-Up Agreement” means the Closing Shares Lock-Up Agreement, dated the Closing Date,
by and among Biovest and the Lenders with respect to limitations on a Lender’s sale of any of the Closing Shares, as it may be amended, modified or supplemented. 

“Code” has the meaning given such term in Section 16(h). 

“Collateral” means all of Biovest’s property and assets, whether real or personal, tangible or
intangible, and whether now owned or hereafter acquired, or in which it now has or at any time in the future may acquire any right, title or interests including all of the following property in which it now has or at any time in the future may
acquire any right, title or interest: 
  

	 	(a)	all Inventory; 

  

	 	(b)	all Equipment; 

  

	 	(c)	all Fixtures; 

  

	 	(d)	all Goods; 

  

	 	(e)	all General Intangibles; 

  

	 	(f)	all Accounts; 

  

	 	(g)	all Deposit Accounts, other bank accounts and all funds on deposit therein; 

 

	 	(h)	all Investment Property; 

  

	 	(i)	all Equity Interests; 

  

	 	(j)	all Chattel Paper; 

  

	 	(k)	all Letter-of-Credit Rights; 

  

	 	(l)	all Instruments; 

  

	 	(m)	all Commercial Tort Claims; 

  

	 	(n)	all Books and Records; 

  

	 	(o)	all Intellectual Property; 

  

	 	(p)	all Documents; 

(q)       all Supporting Obligations including letters of credit and guarantees issued
in support of Accounts, Chattel Paper, General Intangibles and Investment Property; 

  
 5 

(r)      (i)      all money, cash and cash equivalents and
(ii) all cash held as cash collateral and all other cash or property at any time on deposit with or held by the Agent for the account of Biovest (whether for safekeeping, custody, pledge, transmission or otherwise); and 

(s)      all products and Proceeds of all or any of the foregoing, tort claims and all
claims and other rights to payment including (i) insurance claims against third parties for loss of, damage to, or destruction of, the foregoing Collateral and (ii) payments due or to become due under leases, licenses, rentals and hires of
any or all of the foregoing and Proceeds payable under, or unearned premiums with respect to, policies of insurance in whatever form. 
 “Commercial Tort Claims” means all “commercial tort claims,” as such term is defined in the UCC, now owned or hereafter acquired by any Person. 

“Compromise Order” means the Order Granting Debtors’ Motion for Approval of Settlement Between the
Debtors and Laurus Master Fund, Ltd. (in Liquidation) and its Affiliates and Assignees, Pursuant to 11 U.S.C. § 105(a) and Rule 9019(a) of the Federal Rules of Bankruptcy Procedure dated June 8, 2010, entered in the Bankruptcy Cases, as
such order may be amended, modified or supplemented. 
 “Confirmation Order” means the Order
Confirming First Amended Joint Plan of Reorganization of Biovest International, Inc. Biovax, Inc., AutovaxID, Inc., Biolender, LLC and Biolender II, LLC under Chapter 11 of Title 11, United States Code Dated as of August 16, 2010, as Modified,
Pursuant to 11 U.S.C. § 1129 dated November 2, 2010, entered in the Bankruptcy Cases, as such order may be amended, modified or supplemented. 
 “Confirmed Plan” means the Joint Plan as confirmed by the Confirmation Order. 
 “Contract Rate” has the meaning given such term in the BVTI Term Notes. 
 “Contractual Obligation” means, with respect to any Person, any provision of any indenture, mortgage, deed of trust, contract, undertaking, agreement or other instrument to which such
Person is a party or by which it or any of its property is bound or to which any of its property is subject. 

“Conversion Shares” means any shares of Biovest Common Stock issued upon conversion in whole or in part
of the BVTI Term Notes. 
 “Creditor Parties” has the meaning given such term in the preamble.

 “Default” means any act or event which, with the giving of notice or passage of time or
both, would constitute an Event of Default. 
 “Deposit Accounts” means all “deposit
accounts,” as such term is defined in the UCC, now or hereafter held in the name of any Person. 

“Disclosure Controls” has the meaning given such term in Section 12(f)(i). 

  
 6 

 “Documents” means all “documents,” as such term
is defined in the UCC, now owned or hereafter acquired by any Person, wherever located, including all bills of lading, dock warrants, dock receipts, warehouse receipts, and other documents of title, whether negotiable or non-negotiable. 

“Effective Date” means the Effective Date as defined in the Confirmed Plan. 

“Equipment” means all “equipment,” as such term is defined in the UCC, now owned or hereafter
acquired by any Person, wherever located, including any and all machinery, apparatus, equipment, fittings, furniture, Fixtures, motor vehicles and other tangible personal property (other than Inventory) of every kind and description that may be now
or hereafter used in such Person’s operations or that are owned by such Person or in which such Person may have an interest, and all parts, accessories and accessions thereto and substitutions and replacements therefor. 

“Equity Interests” shall mean, with respect to any Person, any and all shares, rights to purchase,
options, warrants, general, limited or limited liability partnership interests, member interests, units, participations or other equivalents of or interest in (regardless of how designated) equity of such Person, whether voting or nonvoting,
including common stock, preferred stock, convertible securities or any other “equity security” (as such term is defined in Rule 3a11-1 of the General Rules and Regulations promulgated by the SEC (or any successor thereto) under the
Exchange Act). 
 “Event of Default” means the occurrence of any of the events set forth in
Section 20. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended.

 “Exchange Act Filings” means Biovest’s filings under the Exchange Act made prior to the
date of this Agreement. 
 “Excluded Taxes” means, with respect to any Creditor Party, taxes
imposed on or measured by its overall net income and franchise taxes imposed on it in lieu of net income taxes, by the jurisdiction (or any political subdivision thereof) under the laws of which such Creditor Party is incorporated or organized or by
the jurisdiction (or any political subdivision thereof) in which the principal place of management or applicable lending office of such Creditor Party is located. 

“Exit Lender” means Corps Real, LLC, an Illinois limited liability company. 

“Exit Lender Credit Facility” means the debtor in possession financing facility between Biovest and the
Exit Lender as approved by orders of the Bankruptcy Court, pursuant to which the Exit Lender has made, and may continue to make, extensions of credit available to Biovest in the maximum amount of $3,000,000. 

“Exit Lender Subordination Agreement” means the Subordination Agreement, dated the Closing Date, by and
between the Agent and the Exit Lender, as it may be amended, modified or supplemented. 

  
 7 

 “Final Order” means (a) an order, judgment, ruling or
other decree (or any revision, modification or amendment thereto) issued and entered by the Bankruptcy Court or by any state or other federal court as may have jurisdiction over any proceeding in connection with the Bankruptcy Cases for the purpose
of such proceeding, which order, judgment, ruling or other decree has not been reversed, vacated, stayed, modified or amended and as to which (i) no appeal, petition for review, reargument, rehearing, reconsideration or certiorari has been
taken and is pending and the time for the filing of such appeal, petition for review, reargument, rehearing, reconsideration or certiorari has expired, or (ii) such appeal or petition has been heard and dismissed or resolved and the time to
further appeal or petition has expired with no further appeal or petition pending; or (b) a stipulation or other agreement entered into which has the effect of any such aforesaid order, judgment, ruling or other decree with like finality.

 “Financial Reporting Controls” has the meaning given such term in Section 12(f)(ii).

 “FINRA” has the meaning given such term in Section 13(b). 

“Fixtures” means all “fixtures,” as such term is defined in the UCC, now owned or hereafter
acquired by any Person. 
 “GAAP” means generally accepted accounting principles in effect from
time to time in the United States of America. 
 “General Intangibles” means all “general
intangibles,” as such term is defined in the UCC, now owned or hereafter acquired by any Person and in any event shall include all right, title and interest that such Person may now or hereafter have in or under any contract, all Payment
Intangibles, customer lists, Intellectual Property, interests in partnerships, joint ventures and other business associations, permits, proprietary or confidential information, inventions (whether or not patented or patentable), technical
information, procedures, designs, knowledge, know-how, Software, data bases, data, skill, expertise, experience, processes, models, drawings, materials, Books and Records, Goodwill (including the Goodwill associated with any Intellectual Property),
all rights and claims in or under insurance policies (including insurance for fire, damage, loss, and casualty, whether covering personal property, real property, tangible rights or intangible rights, all liability, life, key-person, and business
interruption insurance, and all unearned premiums), uncertificated securities, choses in action, deposit accounts, rights to receive tax refunds and other payments, rights to receive dividends, distributions, cash, Instruments and other property in
respect of or in exchange for pledged Equity Interests and Investment Property, and rights of indemnification. 

“Goods” means all “goods,” as such term is defined in the UCC, now owned or hereafter acquired
by any Person, wherever located, including embedded software to the extent included in “goods” as defined in the UCC, manufactured homes, fixtures, standing timber that is cut and removed for sale and unborn young of animals. 

“Goodwill” means all goodwill, trade secrets, proprietary or confidential information, technical
information, procedures, formulae, quality control standards, designs, operating and training manuals, customer lists, and distribution agreements now owned or hereafter acquired by any Person. 

  
 8 

 “Governmental Authority” means any nation or government,
any state or other political subdivision thereof, and any agency, department or other entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government. 

“Guaranty Obligation” means, as applied to any Person, any direct or indirect liability, contingent or
otherwise, of such Person for any Indebtedness, lease, dividend or other obligation (the “primary obligation”) of another Person (the “primary obligor”), if the purpose or intent of such Person in incurring such liability, or the
economic effect thereof, is to guarantee such primary obligation or provide support, assurance or comfort to the holder of such primary obligation or to protect or indemnify such holder against loss with respect to such primary obligation, including
(a) the direct or indirect guaranty, endorsement (other than for collection or deposit in the ordinary course of business), co-making, discounting with recourse or sale with recourse by such Person of any primary obligation, (b) the
incurrence of reimbursement obligations with respect to any letter of credit or bank guarantee in support of any primary obligation, (c) the existence of any Lien, or any right, contingent or otherwise, to receive a Lien, on the property of
such Person securing any part of any primary obligation and (d) any liability of such Person for a primary obligation through any Contractual Obligation (contingent or otherwise) or other arrangement (i) to purchase, repurchase or
otherwise acquire such primary obligation or any security therefor or to provide funds for the payment or discharge of such primary obligation (whether in the form of a loan, advance, stock purchase, capital contribution or otherwise), (ii) to
maintain the solvency, working capital, equity capital or any balance sheet item, level of income or cash flow, liquidity or financial condition of any primary obligor, (iii) to make take-or-pay or similar payments, if required, regardless of
non-performance by any other party to any Contractual Obligation, (iv) to purchase, sell or lease (as lessor or lessee) any property, or to purchase or sell services, primarily for the purpose of enabling the primary obligor to satisfy such
primary obligation or to protect the holder of such primary obligation against loss or (v) to supply funds to or in any other manner invest in, such primary obligor (including to pay for property or services irrespective of whether such
property is received or such services are rendered); provided, however, that “Guaranty Obligations” shall not include (x) endorsements for collection or deposit in the ordinary course of business and (y) product warranties given
in the ordinary course of business. The outstanding amount of any Guaranty Obligation shall equal the outstanding amount of the primary obligation so guaranteed or otherwise supported or, if lower, the stated maximum amount for which such Person may
be liable under such Guaranty Obligation. 
 “Hedging Agreement” means any Interest Rate
Contract, foreign exchange, swap, option or forward contract, spot, cap, floor or collar transaction, any other derivative instrument and any other similar speculative transaction and any other similar agreement or arrangement designed to alter the
risks of any Person arising from fluctuations in any underlying variable. 
 “Indebtedness” of
any Person means, without duplication, any of the following, whether or not matured: (a) all indebtedness for borrowed money (including, without limitation, all principal, interest, fees and charges relating thereto), (b) all obligations
evidenced by notes, bonds, debentures or similar instruments, (c) all reimbursement and all obligations with respect to (i) letters of credit, bank guarantees or bankers’ acceptances or (ii) surety, customs, reclamation or
performance bonds (in each case not related to judgments or litigation) other than those entered into in the ordinary course of business, (d) all obligations to pay the deferred 

  
 9 

 
purchase price of property or services, other than trade payables incurred in the ordinary course of business, (e) all obligations created or arising under any conditional sale or other
title retention agreement, regardless of whether the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such property, (f) all Capitalized Lease Obligations,
(g) all payments that would be required to be made in respect of any Hedging Agreement in the event of a termination (including an early termination) on the date of termination and (h) all Guaranty Obligations for obligations of any other
Person constituting Indebtedness of such other Person; provided, however, that the items in each of clauses (a) through (h) above shall constitute “Indebtedness” of such Person solely to the extent, directly or indirectly,
(x) such Person is liable for any part of any such item, (y) any such item is secured by a Lien on such Person’s property or (z) any other Person has a right, contingent or otherwise, to cause such Person to become liable for any
part of any such item or to grant such a Lien. 
 “Indemnified Person” has the meaning given
such term in Section 27. 
 “Instruments” means all “instruments,” as such term
is defined in the UCC, now owned or hereafter acquired by any Person, wherever located, including all certificated securities and all promissory notes and other evidences of indebtedness, other than instruments that constitute, or are a part of a
group of writings that constitute, Chattel Paper. 
 “Intellectual Property” means any and all
of the following, throughout the world: patents, trademarks, trade names, corporate names, fictitious business names, internet domain names, trade styles, service marks, logos, and other source of business identifiers and the goodwill symbolized by
and connected with the use thereof; copyrights, mask works, designs, inventions, trade secrets, information, databases, rights of publicity, software, and any other proprietary rights and processes; any licenses to use any of the foregoing owned by
a third party; registrations, applications and recordings pertaining to any of the foregoing; and rights to sue for past, present and future infringement, dilution, misappropriation, or other violation of any of the foregoing. 

“Intellectual Property Security Agreement” means the Grant of Security Interest in Intellectual
Property, dated the Closing Date, from Biovest and Analytica in favor of the Agent, as each such agreement may be amended, modified or supplemented. 
 “Interest Rate Contracts” means all interest rate swap agreements, interest rate cap agreements, interest rate collar agreements and interest rate insurance. 

“Inventory” means all “inventory,” as such term is defined in the UCC, now owned or hereafter
acquired by any Person, wherever located, including all inventory, merchandise, goods and other personal property that are held by or on behalf of such Person for sale or lease or are furnished or are to be furnished under a contract of service or
that constitute raw materials, work in process, finished goods, returned goods, or materials or supplies of any kind, nature or description used or consumed or to be used or consumed in such Person’s business or in the processing, production,
packaging, promotion, delivery or shipping of the same, including all supplies and embedded software. 

  
 10 

 “Investment Property” means all “investment
property,” as such term is defined in the UCC, now owned or hereafter acquired by any Person, wherever located. 
 “Investor DIP Lenders” means Empery Asset Master, Ltd., Hartz Capital Investments, LLC, and the other parties listed on the Schedule of Buyers attached to the Securities Purchase
Agreement. 
 “Joint Plan” means the First Amended Joint Plan of Reorganization of Biovest
International, Inc., Biovax, Inc., AutovaxID, Inc., Biolender, LLC, and Biolender II, LLC under Chapter 11 of Title 11, United States Code dated as of August 16, 2010, as modified by the First Modification to First Amended Joint Plan of
Reorganization of Biovest International, Inc., Biovax, Inc., AutovaxID, Inc., Biolender, LLC, and Biolender II, LLC under Chapter 11 of Title 11, United States Code dated as of October 25, 2010, and all exhibits thereto, as the same may be
further amended, supplemented, modified or amended and restated from time to time in accordance with the provisions of the Joint Plan and the Bankruptcy Code. 
 “Lenders” has the meaning given such term in the preamble. 
 “Letter-of-Credit Rights” means “letter-of-credit rights,” as such term is defined in the UCC, now owned or hereafter acquired by any Person, including rights to payment or
performance under a letter of credit, whether or not such Person, as beneficiary, has demanded or is entitled to demand payment or performance. 
 “Lien” means any mortgage, security deed, deed of trust, pledge, hypothecation, assignment, security interest, lien (whether statutory or otherwise), charge, claim or encumbrance, or
preference, priority or other security agreement or preferential arrangement held or asserted in respect of any asset of any kind or nature whatsoever including any conditional sale or other title retention agreement, any lease having substantially
the same economic effect as any of the foregoing, and the filing of, or agreement to give, any financing statement under the UCC or comparable law of any jurisdiction. 

“Material Adverse Effect” means a material adverse effect on (a) the business, assets, liabilities,
condition (financial or otherwise), properties, operations or prospects of Biovest (taken individually and as a whole), (b) Biovest’s ability to pay or perform the Obligations in accordance with the terms hereof or any Ancillary Agreement,
(c) the value of the Collateral, the Agent’s Liens on the Collateral or the priority of any such Liens, or (d) the practical realization of the benefits of the Creditor Parties’ rights and remedies under this Agreement and the
Ancillary Agreements. 
 “Maximum Legal Rate” has the meaning given to such term in
Section 5(a)(ii). 
 “Net Short Position” has the meaning given to such term in
Section 16(i). 
 “Non-Excluded Taxes” means all Taxes other than (i) Excluded Taxes
and (ii) Other Taxes. 
 “Non-U.S. Lender” has the meaning given to such term in
Section 5(a)(vii). 

  
 11 

 “Obligations” means all advances, debts, liabilities,
obligations, covenants and duties owing by Biovest to any Creditor Party (or any corporation that directly or indirectly controls or is controlled by or is under common control with any of them) of every kind and description arising from or relating
to the BVTI Term Loans, this Agreement, and any Ancillary Agreement (whether or not evidenced by any note or other instrument and whether or not for the payment of money or the performance or non-performance of any act), direct or indirect, absolute
or contingent, due or to become due, contractual or tortious, liquidated or unliquidated, whether existing by operation of law or otherwise, now existing or hereafter arising including any debt, liability or obligation owing from Biovest to others
which any Creditor Party may have obtained by assignment or otherwise and further including all interest (including interest accruing at the then applicable rate provided in this Agreement after the maturity of the BVTI Term Loans and interest
accruing at the then applicable rate provided in this Agreement after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, whether or not a claim for post-filing or post-petition
interest is allowed or allowable in such proceeding), charges or any other payments that Biovest is required to make by law or otherwise arising under or as a result of this Agreement or the Ancillary Agreements, together with all reasonable
expenses and reasonable attorneys’ fees chargeable to Biovest’s accounts or incurred by any Creditor Party in connection therewith. 
 “Other Taxes” means any and all present or future stamp or documentary taxes or any other excise or property taxes, charges or similar levies arising from any payment made hereunder or
from the execution, delivery or enforcement of, or otherwise with respect to, this Agreement or any Ancillary Agreement. 
 “Payment Intangibles” means all “payment intangibles,” as such term is defined in the UCC, now owned or hereafter acquired by any Person, including a General Intangible under
which the Account Debtor’s principal obligation is a monetary obligation. 
 “Permitted
Liens” means (a) Liens securing the Indebtedness of Biovest to the Exit Lender pursuant to the Exit Lender Credit Facility; (b) Liens of carriers, warehousemen, artisans, bailees, mechanics and materialmen incurred in the ordinary
course of business securing sums not overdue; (c) Liens incurred in the ordinary course of business in connection with worker’s compensation, unemployment insurance or other forms of governmental insurance or benefits, relating to
employees, securing sums (i) not overdue or (ii) being diligently contested in good faith provided that adequate reserves with respect thereto are maintained on the books of Biovest, in conformity with GAAP; (d) licenses of
Intellectual Property granted by Biovest prior to the date hereof, and licenses of Intellectual Property granted in the ordinary course of business consistent with past practices or consistent with Biovest’s business plan or strategy;
(e) Liens in favor of the Agent or the other Creditor Parties; (f) Liens for Taxes (i) not yet due or (ii) being diligently contested in good faith by appropriate proceedings, provided that adequate reserves with respect thereto
are maintained on the books of Biovest, in conformity with GAAP; and which have no effect on the priority of the Liens in favor of the Agent or the other Creditor Parties or the value of the Collateral in which the Agent and each other Creditor
Party has a Lien; (g) Purchase Money Liens securing Purchase Money Indebtedness to the extent not prohibited by this Agreement; (h) Liens contemplated by the Confirmed Plan; (i) Liens granted by orders of the Bankruptcy Court entered
in the Bankruptcy Cases; and (j) Liens granted to (x) the landlord of Biovest’s Minnesota facility over assets and leasehold improvements at such facility in 

  
 12 

 
consideration of leasehold improvements made by such landlord, and (y) the City of Coon Rapids, Minnesota over the same assets and leasehold improvements in exchange for a loan by such city
to Biovest. 
 “Person” means any individual, sole proprietorship, partnership, limited
liability partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, public benefit corporation, entity or government (whether federal, state, county, city, municipal or
otherwise, including any instrumentality, division, agency, body or department thereof), and shall include such Person’s successors and assigns. 
 “Petition Date” has the meaning given such term in the Background. 
 “Prepetition Debt” has the meaning given such term in the Background. 
 “Prepetition Lenders” has the meaning given such term in the Background. 
 “Principal Market” means any of the following markets or exchanges on which the Accentia Common Stock is listed or quoted for trading on the date in question: the New York Stock Exchange,
the NYSE AMEX, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the OTCQB Marketplace, or the OTC Bulletin Board (or any successors to any of the foregoing). 

“Proceeds” means “proceeds,” as such term is defined in the UCC and, in any event, shall
include: (a) any and all proceeds of any insurance, indemnity, warranty or guaranty payable to Biovest or any other Person from time to time with respect to any Collateral; (b) any and all payments (in any form whatsoever) made or due and
payable to Biovest from time to time in connection with any requisition, confiscation, condemnation, seizure or forfeiture of any Collateral by any governmental body, Governmental Authority, bureau or agency (or any person acting under color of
Governmental Authority); (c) any claim of Biovest against third parties (i) for past, present or future infringement of any Intellectual Property or (ii) for past, present or future infringement or dilution of any trademark or
trademark license or for injury to the goodwill associated with any trademark, trademark registration or trademark licensed under any trademark license; (d) any recoveries by Biovest against third parties with respect to any litigation or
dispute concerning any Collateral, including claims arising out of the loss or nonconformity of, interference with the use of, defects in, or infringement of rights in, or damage to, Collateral; (e) all amounts collected on, or distributed on
account of, other Collateral, including dividends, interest, distributions and Instruments with respect to Investment Property and pledged Equity Interests; (f) any and all other amounts, rights to payment or other property acquired upon the
sale, lease, license, exchange or other disposition of Collateral and all rights arising out of Collateral; and (g) proceeds of any purchase order. 
 “Purchase Money Indebtedness” means (a) any indebtedness incurred for the payment of all or any part of the purchase price of any fixed asset, including indebtedness under
capitalized leases, (b) any indebtedness incurred for the sole purpose of financing or refinancing all or any part of the purchase price of any fixed asset, and (c) any renewals, extensions or refinancings thereof (but not any increases in
the principal amounts thereof outstanding at that time). 

  
 13 

 “Purchase Money Lien” means any Lien upon any fixed assets
that secures the Purchase Money Indebtedness related thereto but only if such Lien shall at all times be confined solely to the asset the purchase price of which was financed or refinanced through the incurrence of the Purchase Money Indebtedness
secured by such Lien and only if such Lien secures only such Purchase Money Indebtedness. 

“Register” has the meaning given such term in Section 24(b). 

“Royalty Assignment Termination Agreement” means the Royalty Assignment Termination Agreement, dated the
Closing Date, by and between Accentia and certain of the Prepetition Lenders and their assignees terminating the assignment by Accentia to such parties of the right to receive royalties for the sale of the Biovest Biologic Products. 

“Royalty Termination Agreements” means the Royalty Termination Agreements, dated the Closing Date, by
and between Biovest, on the one hand, and certain of the Prepetition Lenders and the Agent, on the other hand, providing for the termination of any and all rights granted to the Prepetition Lenders and the Agent, prior to the Petition Date, to
receive royalties from the Biovest Biologic Products. 
 “SEC” means the Securities and
Exchange Commission. 
 “Securities Act” means the Securities Act of 1933, as amended.

 “Securities Purchase Agreement” means the Securities Purchase Agreement dated as of
October 19, 2010, by and among Biovest and the Investor DIP Lenders. 
 “Security
Documents” means all security agreements, mortgages, cash collateral deposit letters, pledges and other agreements which are executed in connection with this Agreement by Biovest or any of its Affiliates in favor of the Agent for the
ratable benefit of the Creditor Parties. 
 “Software” means all “software,” as such
term is defined in the UCC, now owned or hereafter acquired by any Person, including all computer programs and all supporting information provided in connection with a transaction related to any program. 

“Stock Acquisition Limitation” has the meaning given such term in Section 16(h). 

“Subsidiary” means, with respect to any Person, (a) any other Person whose shares of stock or other
ownership interests having ordinary voting power (other than stock or other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the directors or other governing body of such other Person,
are owned, directly or indirectly, by such Person or (b) any other Person in which such Person owns, directly or indirectly, more than fifty percent (50%) of the Equity Interests at such time. 

“Supporting Obligations” means all “supporting obligations,” as such term is defined in the
UCC. 

  
 14 

 “Taxes” means any and all present or future taxes, duties,
levies, imposts, deductions, assessments, fees, withholdings or similar charges, and all liabilities with respect thereto. 
 “Term A Notes” has the meaning given such term in Section 2(a)(i). 
 “Term B Notes” has the meaning given such term in Section 2(a)(i). 
 “Termination Date” has the meaning given such term in Section 14(d)(i). 
 “UCC” means the Uniform Commercial Code as the same may, from time to time, be in effect in the State of New York; provided, that in the event that, by reason of mandatory provisions of
law, any or all of the perfection or priority of, or remedies with respect to, the Agent’s Lien on any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, the term
“UCC” shall mean the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions of this Agreement relating to such perfection, priority or remedies and for purposes of definitions related to such
provisions; provided further, that to the extent that the UCC is used to define any term herein or in any Ancillary Agreement and such term is defined differently in different Articles or Divisions of the UCC, the definition of such term contained
in Article 9 or Division 9 shall govern. 
 “Warrant Termination Agreements” means the Warrant
Termination Agreements, dated the Closing Date, by and between Biovest and Accentia, on the one hand, and certain of the Prepetition Lenders, on the other hand, terminating the Biovest Warrants. 

  
 15 

 INDEX TO EXHIBITS  
 Exhibit A – Biovest Warrants 
 Exhibit B – BVTI Term Notes 

Exhibit C – Accentia Limited Guaranty 
 Exhibit D – Accentia Subordination Agreement 
 Exhibit E – Exit Lender
Subordination Agreement 
 Exhibit F – Accentia Pledge Agreement 
 Exhibit G – Analytica Security Agreement 
 Exhibit H – Analytica Guaranty

 Exhibit I – Closing Shares Lock-Up Agreement 
 Exhibit J – Biovest Contingent Payment Agreement 
 Exhibit K –
Intellectual Property Security Agreements 
 Exhibit L – Biovest Amendments to Organizational Documents 

Exhibit M – Royalty Assignment Termination Agreement 
 Exhibit N – AutovaxID Royalty Termination Agreement 
 Exhibit O – Warrant
Termination Agreements 
 Exhibit P – Royalty Termination Agreements 
 Exhibit Q – Accentia Royalty Termination Agreement 

 Exhibit A 
 Biovest Warrants 
  

											
	  
 Name
	  	Option
Date	    	Expiration
Date	    	Option
Price	    	Shares
Originally
Subject to
Warrant	 
					
	Laurus Master Fund, Ltd.	  	  3/31/2006	    	  3/31/2021	    	$0.01	    	 	18,087,889	  
	Laurus Master Fund, Ltd.	  	10/31/2006	    	10/31/2013	    	$0.01	    	 	10,000,000	  
	Valens U.S. SPV I, LLC	  	  9/22/2008	    	  9/21/2013	    	$0.40	    	 	  1,015,625	  

 Exhibit B 
 BVTI Term Notes 
 See attached. 

 Exhibit C 
 Accentia Limited Guaranty 
 See attached. 

 Exhibit D 
 Accentia Subordination Agreement 
 See attached. 

 Exhibit E 
 Exit Lender Subordination Agreement 
 See attached. 

 Exhibit F 
 Accentia Pledge Agreement 
 See attached. 

 Exhibit G 
 Analytica Security Agreement 
 See attached. 

 Exhibit H 
 Analytica Guaranty 
 See attached. 

 Exhibit I 
 Closing Shares Lock-Up Agreement 
 See attached. 

 Exhibit J 
 Biovest Contingent Payment Agreement 
 See attached. 

 Exhibit K 
 Intellectual Property Security Agreements 
 See attached. 

 Exhibit L 
 Biovest Amendments to Organizational Documents 
 See attached. 

 Exhibit M 
 Royalty Assignment Termination Agreement 
 See attached. 

 Exhibit N 
 AutovaxID Royalty Termination Agreement 
 See attached. 

 Exhibit O 
 Warrant Termination Agreements 
 See attached. 

 Exhibit P 
 Royalty Termination Agreements 
 See attached. 

 Exhibit Q 
 Accentia Royalty Termination Agreement 
 See attached. 

 INDEX TO SCHEDULES 
 Schedule 2(a)(i) – Amount of BVTI Term Notes 
 Schedule 2(b) – Number and
Allocation of Closing Shares 
 Schedule 7(c) – Intellectual Property Filings 

Schedule 7(n) – Bank Accounts 

Schedule 7(o) – Corporate Information 
 Schedule 12(b) – Subsidiaries 
 Schedule 12(c) – Capitalization; Voting
Rights 
 Schedule 12(g) – Title to Properties and Assets; Liens 
 Schedule 12(h) – Registration Rights and Voting Rights 
 Schedule 12(n) –
Name; Locations of Offices, Records and Collateral 

 Schedule 2(a)(i) 

Amount of BVTI Term Notes 
  

					
	 Term A Notes (Total: $24,900,000)
	  			
		
	 Erato Corp.
	  	$	1,333,334.00	  
	 Valens Offshore SPV I, Ltd.
	  	$	4,644,640.00	  
	 Valens Offshore SPV II, Corp.
	  	$	12,694,883.00	  
	 Valens U.S. SPV I, LLC
	  	$	3,216,338.00	  
	 PSource Structured Debt Limited
	  	$	3,010,805.00	  
		
	 Term B Notes (Total: $4,160,000)
	  			
		
	 Laurus Master Fund Ltd. (In Liquidation)
	  	$	500,000.00	  
	 Valens Offshore SPV I, Ltd.
	  	$	1,980,592.00	  
	 Valens Offshore SPV II, Corp.
	  	$	836,313.00	  
	 Valens U.S. SPV I, LLC
	  	$	155,175.00	  
	 PSource Structured Debt Limited
	  	$	687,920.00	  

 Schedule (2)(b) 

Number and Allocation of Closing Shares 
  

Total Number of Closing Shares: 14,834,782 
  

							
	 	  	Number of Shares	 	  	Percentage Allocation
	 Laurus Master Fund Ltd. (In Liquidation)
	  	 	1,877,510  	  	  	      13%
	 Valens Offshore SPV I, Ltd.
	  	 	7,320,877  	  	  	      49%
	 Valens Offshore SPV II, Corp.
	  	 	0  	  	  	        0%
	 Valens U.S. SPV I, LLC
	  	 	1,036,468  	  	  	        7%
	 PSource Structured Debt Limited
	  	 	4,599,927  	  	  	      31%

 Schedule 7(c) 

 
 Intellectual Property Filings 

 
 None 

 Schedule 7(n) 
 Bank Accounts 
  
  

	1.	Wachovia, NA 

 Jacksonville
Beach, FL 
 Tel: 813/225-4307 (Lora Hernandez (Tampa)) 
 Account No. 2000045051452 
 Account Name: Biovest International, Inc. 

 

	2.	Wells Fargo Bank NA 

 Anoka
Business Banking 
 PO Box B514 
 Minneapolis, MN 55479 
 Tel: 800/225-5935 

Account No. 1000180093 
 Account Name: Biovest International, Inc. 

 Schedule 7(o) 
 Corporate Information 
  
  

					
	Legal Name:	    	Biovest International, Inc.	  	
	Jurisdiction of Organization:	    	Delaware	  	
	Organizational ID Number:	    	080602759	  	
	Corporate Offices:	    	324 South Hyde Park Avenue	  	
		    	Suite 350	  	
		    	Tampa, Florida 33606	  	

 Schedule 12(b) 

Subsidiaries 
  

					
	 Subsidiary Name
	  	 Percentage of Ownership by Biovest International, Inc.

	1.	  	Biovax, Inc.*	  	            100%
	2.	  	AutovaxID, Inc.*	  	            100%
	3.	  	Biolender, LLC*	  	            Sole Member
	4.	  	Biolender II, LLC*	  	            Sole Member

 * Each of these entities, pursuant to the Confirmed Plan, have been substantively consolidated with Biovest and shall be dissolved promptly following the Effective Date. 

 Schedule 12(c) 

Capitalization; Voting Rights 
  

 
  

					
	 Warrants Outstanding (excludes Biovest Warrants)
	  	 	17,647,627	  
		
	 Employee Incentive Stock Options Outstanding
	  	 	26,742,486	  

 Schedule 12(g) 

Title to Properties and Assets; Liens 
 None 

 Schedule 12(h) 

Registration Rights and Voting Rights 
 None 

 Schedule 12(n) 

Name; Locations of Offices, Records and Collateral 

 

			
	Legal Name:	  	Biovest International, Inc.
	Type of Entity:	  	Corporation
	Jurisdiction of Organization:	  	Delaware
	Organizational ID Number:	  	3362955
	Corporate Offices:	  	324 South Hyde Park Avenue
		  	Suite 350
		  	Tampa, Florida 33606
		
	Manufacturing Facilities:	  	8500 Evergreen Boulevard, NW
		  	Coon Rapids, MN 55433Secured Term A Note between Biovest and Erato Corp

 Exhibit 10.2 
 THIS NOTE IS EXECUTED AND DELIVERED AS PART OF THE CONFIRMED FIRST AMENDED JOINT PLAN OF REORGANIZATION OF BIOVEST INTERNATIONAL, INC., BIOVAX, INC., AUTOVAXID, INC., BIOLENDER, LLC AND BIOLENDER II,
LLC, AS AMENDED, IN THE JOINTLY ADMINISTERED CHAPTER 11 CASE STYLED IN RE: ACCENTIA BIOPHARMACEUTICALS, INC., CASE NO. 8:08-BK-17795-KRM, IN THE UNITED STATES BANKRUPTCY COURT FOR THE MIDDLE DISTRICT OF FLORIDA, TAMPA DIVISION, AND IS,
THEREFORE, EXEMPT FROM DOCUMENTARY STAMP TAX PURSUANT TO 11 U.S.C. §1146(a). 
 THIS NOTE AND THE COMMON STOCK
ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE MAY NOT BE SOLD, OFFERED FOR
SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE OR SUCH COMMON STOCK UNDER SUCH SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR (B) AN EXEMPTION FROM SUCH REGISTRATION
REQUIREMENTS. 
 THIS NOTE IS ISSUED IN REGISTERED FORM. UNLESS THIS NOTE IS PRESENTED BY THE HOLDER (AS DEFINED BELOW)
TO THE COMPANY (AS DEFINED BELOW) FOR REGISTRATION OF TRANSFER, EXCHANGE, CONVERSION OR PAYMENT, ANY TRANSFER, EXCHANGE OR OTHER USE HEREOF SHALL BE VOID AND PAYMENT SHALL NOT BE MADE. 

TRANSFER OF ALL OR ANY PORTION OF THIS NOTE IS PERMITTED SUBJECT TO THE PROVISIONS SET FORTH IN THE SECURITY AGREEMENT (AS DEFINED
BELOW). 
 SECURED TERM A NOTE 

FOR VALUE RECEIVED, BIOVEST INTERNATIONAL, INC., a Delaware corporation with a principal business
address of 324 South Hyde Park Avenue, Suite 350, Tampa, Florida 33606 (the “Company”), hereby promises to pay to ERATO CORP., a Delaware corporation with a principal business address of c/o Laurus Capital Management LLC, 875 Third
Avenue, 3rd Floor, New York, New York 10022 (the
“Holder”) or its registered assigns or successors, the sum of One Million Three Hundred Thirty Three Thousand Three Hundred Thirty Four Dollars ($1,333,334.00) (the “Principal Amount”), together with any accrued and
unpaid interest hereon, on November 17, 2012 or such earlier date as required pursuant to the terms hereof whether by acceleration or otherwise (the “Maturity Date”), if not sooner indefeasibly paid in full. 

Capitalized terms used herein without definition shall have the meanings ascribed to such terms in that certain Term Loan
and Security Agreement dated as of November 17, 2010 (as amended, restated, modified and/or supplemented from time to time, the “Security Agreement”) among the Company, the Holder, each Lender from time to time party thereto
and LV Administrative Services, Inc., as administrative and collateral agent for the Holder and the other 

 
Lenders (the “Agent” together with the Holder and the other Lenders party thereto, collectively, the “Credit Parties”). 

This Secured Term A Note (the “Note”) is secured by a security interest and lien on all assets of the
Company, including Accentia’s pledge of certain of the shares of Biovest Common Stock it holds, in each case in accordance with the terms of the Security Agreement and the Ancillary Agreements. This Note is guaranteed by Accentia in accordance
with and subject to the terms of the Accentia Limited Guaranty. The indebtedness represented by this Note shall be a senior obligation of the Company, except as otherwise expressly provided in the Confirmed Plan for administrative expense claim
carve-outs approved by orders of the Bankruptcy Court and except that the Company’s obligations hereunder shall be junior to the obligations of the Company to the Exit Lender in a maximum amount of $3,000,000 in accordance with the terms of a
Subordination Agreement dated the date hereof between the Agent and the Exit Lender. 
 This Note shall be
subject to the terms and provisions of the Confirmed Plan. To the extent that there is any conflict between the terms and provisions of this Note and the terms and provisions of the Confirmed Plan, the terms and provisions of this Note shall
control. 
 The following terms shall apply to this Note: 

ARTICLE I 

CONTRACT RATE AND MATURITY 
 1.1        Contract Rate. Subject to Sections 4.2 and 5.9, interest payable on the outstanding Principal Amount of this Note shall accrue at a simple
interest rate per annum equal to eight percent (8%) (the “Contract Rate”). Interest shall be (i) calculated on the basis of a 365 day year, and (ii) payable on the Maturity Date or upon the date of any Mandatory
Prepayment (as defined below) or Optional Prepayment (as defined below). If a Mandatory Prepayment or Optional Prepayment occurs, accrued and unpaid interest on the portion of the Principal Amount being repaid shall be due and payable at such time.

 1.2        Principal Payments. Subject to Sections 2.2 and
4.3, the outstanding Principal Amount together with any accrued and unpaid interest and any and all other unpaid amounts which are then owing by the Company to the Holder under or in connection with this Note shall be due and payable on the Maturity
Date. 
 ARTICLE II 
 PREPAYMENT 

2.1        Optional Prepayment. The Company may prepay this Note at any
time, in whole or in part, without penalty or premium (“Optional Prepayment”). 

2.2        Mandatory Prepayment. The Company shall prepay this Note as
follows (“Mandatory Prepayment”): 

 (a)        Upon receipt by the Company after the date hereof of cash
proceeds from any capital contribution, loan, issuance of debt or equity, or any source whatsoever that results in cash proceeds to the Company (a “Capital Raise”), the Company

  
 2 

 
shall, within three (3) Business Days following the closing of each such Capital Raise (the “Mandatory Prepayment Date”), prepay the Principal Amount of the Term A Notes in
an aggregate amount for all Term A Notes, collectively, equal to the lesser of (x) thirty percent (30%) of the Net Proceeds (as defined below) of the Capital Raise, or (y) the then outstanding Principal Amount of the Term A Notes,
plus all accrued and unpaid interest on the amount being prepaid; provided, that any such prepayment shall be allocated among the Term A Notes, pro rata, based upon the principal amount outstanding on each of the Term A Notes at the time of closing
of the Capital Raise plus accrued interest on such principal amount being prepaid; provided, however, the total amount of principal and interest being paid shall not exceed thirty percent (30%) of the Net Proceeds from the Capital Raise. The
term “Capital Raise” shall not, in any event, include (i) any amounts borrowed under the Exit Lender Credit Facility by the Company after the date hereof up to a maximum amount equal to the difference between (x) $3,000,000 and
(y) the principal amount outstanding under the Exit Lender Credit Facility as of the date hereof (the “Maximum Borrowing Limit”), or (ii) any new loans made by Accentia to the Company after the date hereof, up to a maximum
amount equal to the Maximum Borrowing Limit; provided, however, that the total amount so excluded from the term “Capital Raise” under subparagraphs (i) and (ii) shall not exceed the Maximum Borrowing Limit. “Net
Proceeds” with respect to a Capital Raise shall mean the gross cash proceeds received from any Capital Raise less any investment banking or similar fees and commissions and legal costs and expenses incurred by the Company directly in
connection with the Capital Raise. The Company shall deliver to the Agent a calculation specifying the amount of the Net Proceeds received within two (2) Business Days following the closing of any Capital Raise. Notwithstanding the foregoing,
if the Capital Raise is from funds provided by Accentia (an “Intercompany Funding”), thirty percent (30%) of the amount proposed to be funded by Accentia in the Intercompany Funding shall first be used by Accentia to prepay the
Accentia Term Notes to the holders thereof and, if the Accentia Term Notes have been paid in full, the balance of such thirty percent (30%) of the Intercompany Funding shall then be used to prepay the Term A Notes (on a pro rata basis) upon the
receipt by the Company of the Intercompany Funding. However, if the Intercompany Funding was made with funds obtained by Accentia from a third party, and if Accentia made a mandatory prepayment under and in accordance with Section 2.2(a) of the
Accentia Term Notes on account of such third party funding (an “Accentia Mandatory Prepayment”), then the combined aggregate prepayment required to be made under the Accentia Term Notes and the Term A Notes pursuant to the preceding
sentence will be reduced by the amount of such Accentia Mandatory Prepayment actually made in respect of such Intercompany Funding. For purposes hereof, cash proceeds received by the Company from the exercise of stock options or stock purchase
warrants shall not constitute a Capital Raise if the stock option or stock purchase warrant was issued prior to the date hereof or issued pursuant to the Confirmed Plan. 

(b)        The Company shall, within sixty (60) days of the end of each
fiscal quarter after the date hereof (each, also, a “Mandatory Prepayment Date”), prepay the Principal Amount of the Term A Notes in an aggregate amount equal to (i) fifty percent (50%) of positive Net Cash Flow (as
defined below) for such fiscal quarter, less (ii) any Biologic Products Capital Expenditures (as defined below) made during such fiscal quarter or during any prior fiscal quarter ending after the date of this Note, until the Principal Amount
and all interest and other payments due under this Note have been paid in full; provided, that, any such prepayment shall be allocated among the Term A Notes, on a pro rata basis, based upon the principal amount outstanding on each of the Term A
Notes at the time of such prepayment plus accrued interest on 

  
 3 

 
such principal amount being prepaid. Notwithstanding the foregoing, any Biologic Products Capital Expenditures made in a prior fiscal quarter will not be deducted as aforesaid to the extent such
expenditures have previously been taken into account in calculating the prepayment amount for any prior fiscal quarter pursuant to this Section 2.2(b). The term “Biologic Products Capital Expenditures” shall mean capital
expenditures of the Company directly related to the development and production of the Biovest Biologic Products, including any capital expenditures incurred by the Company in modifying or expanding its biologics manufacturing facilities, but shall
not include any allocation for corporate overhead or other general and administrative expenses. For this purpose, a capital expenditure is deemed to be made in the fiscal quarter in which the capital asset is capitalized in accordance with GAAP,
consistently applied. The term “Net Cash Flow” shall mean, as calculated in accordance with GAAP, the net cash flows from operating activities as set forth in the Company’s consolidated cash flow statement as it appears as part
of the Company’s consolidated financial statements as reviewed by an independent accounting firm; provided, that Net Cash Flow shall not include (i) cash from research and development grants or contracts to the extent that the terms of the
grant or contract specify a use for such cash or (ii) cash received on up-front customer deposits to cover the cost of raw materials until payment has been made to purchase the applicable raw materials. The Company shall provide Holder, within
fifty (50) days of the end of each fiscal quarter, with financial statements setting forth the Net Cash Flow calculation and containing a reasonably detailed report of all Biologic Products Capital Expenditures. The designation of Biologic
Products Capital Expenditures for purposes of this Section 2.2(b) shall be subject to the approval of the Agent, which approval decision shall be made in good faith and shall not be unreasonably withheld or delayed, and further provided that no
prepayment shall be due under this Section 2.2(b) until such approval decision is communicated to the Company in writing. 
 (c)        On a Mandatory Prepayment Date, the amount required to be paid pursuant to Section 2.2(a) or (b) (the “Mandatory Prepayment
Amount”) shall be paid in immediately available funds to the Holder. In the event the Company fails to pay the Mandatory Prepayment Amount on the Mandatory Prepayment Date as set forth herein, then it shall constitute an Event of Default
hereunder. 
 ARTICLE III 
 CONVERSION OPTION 

3.1        Conversion Election. At any time after the date hereof, the
Company may elect to convert all or a portion of the principal and all accrued and unpaid interest thereon outstanding under this Note into shares of Biovest Common Stock (a “Conversion Election”) upon prior written notice to, and
the written consent of, the Holder. If the Company wishes to make a Conversion Election, the Company shall give notice of such election by delivering an executed and completed notice of conversion in substantially the form of Exhibit A hereto
(appropriately completed) (“Notice of Conversion”) to the Holder and such Notice of Conversion shall provide a breakdown in reasonable detail of the principal and accrued and unpaid interest thereon outstanding under this Note that
are being converted and the calculation of the number of shares of Biovest Common Stock issuable to the Holder on conversion. 
 The number of shares of Biovest Common Stock issuable to the Holder (the “Conversion Shares”) upon its delivery of a Conversion Acceptance (as defined below) shall be equal to
(a)

  
 4 

 
an amount equal to the aggregate portion of the principal and accrued and unpaid interest thereon outstanding under this Note being converted, divided by (b) ninety percent (90%) of the
average closing price publicly reported for the Biovest Common Stock for the ten (10) trading days immediately preceding the date of the Notice of Conversion. 

The Holder shall have five (5) Business Days after receipt of a Notice of Conversion to notify the Company in
writing of whether or not it consents to the Company’s Conversion Election (a “Conversion Acceptance”). If the Holder fails to provide written notice to the Company, within such five (5) Business Day period, the Holder
shall be deemed not to have consented to such Conversion Election. 

3.2        Issuance of Conversion Shares. If the Holder has delivered a
Conversion Acceptance (together with the surrender of this Note), effective as of a Conversion Date (as hereinafter defined) and in accordance with the Notice of Conversion, the Company shall make the appropriate reduction to the Principal Amount
and accrued and unpaid interest thereon outstanding under this Note as entered in its register and its records, and if conversion is in part, issue a new Secured Term A Note in accordance with Section 3.6 hereof. Each date on which a Notice of
Conversion is delivered to the Holder in accordance with the provisions hereof shall be deemed a Conversion Date (a “Conversion Date”). Pursuant to the terms of the Notice of Conversion and if the Holder has delivered a Conversion
Acceptance, the Company shall, within one (1) Business Day after the date of the delivery to the Company of the Conversion Acceptance (together with surrender of this Note), issue instructions to its transfer agent (accompanied by an opinion of
counsel) to transmit the certificates representing the Conversion Shares to the Holder, by crediting the account of the Holder’s designated broker with the Depository Trust Corporation (“DTC”) through its Deposit Withdrawal
Agent Commission (“DWAC”) system within three (3) Business Days after receipt by the Company of the Conversion Acceptance (the “Delivery Date”). In the case of the exercise of the conversion rights set forth
herein and the consent of the Holder to such conversion, the conversion privilege shall be deemed to have been exercised and the Conversion Shares issuable upon such conversion shall be deemed to have been issued upon the date of receipt by the
Holder of the Notice of Conversion. The Holder shall be treated for all purposes as the record holder of the Conversion Shares, unless the Holder provides the Company written instructions to the contrary. 

3.3        Late Payments. The Company understands that a delay in the
delivery of the Conversion Shares in the form required pursuant to this Article III beyond the Delivery Date could result in economic loss to the Holder. As compensation to the Holder for such loss, in addition to all other rights and remedies which
the Holder may have under this Note, applicable law or otherwise, the Company shall pay late payments to the Holder for any late issuance of the Conversion Shares in the form required pursuant to this Article III upon conversion of this Note, in the
amount equal to $500 per Business Day after the Delivery Date. The Company shall, jointly and severally, make any payments incurred under this Section 3.3 in immediately available funds upon demand. 

3.4        Adjustment Provisions. The kind of shares or other securities
to be issued upon conversion as determined pursuant to Section 3.1 shall be subject to adjustment from time to time upon the occurrence of certain events during the period that this conversion right remains outstanding, as follows: 

  
 5 

 (a)        If the Company at any
time shall, by reclassification or otherwise, change the Biovest Common Stock into the same or a different number of securities of any class or classes, this Note, as to the unpaid Principal Amount and the accrued and unpaid interest thereon, shall
thereafter be deemed to evidence the right to purchase an adjusted number of such securities and kind of securities as would have been issuable as the result of such change with respect to the Biovest Common Stock (i) immediately prior to or
(ii) immediately after such reclassification or other change at the sole election of the Holder. 

3.5        Reservation of Shares. During the period this conversion right
remains outstanding, the Company will reserve from its authorized and unissued Biovest Common Stock a sufficient number of shares to provide for the issuance of the Conversion Shares upon the full conversion of this Note. The Company represents
that, upon issuance, the Conversion Shares will be duly and validly issued, fully paid and non-assessable. The Company agrees that its issuance of this Note shall constitute full authority to its officers, agents, and transfer agents who are charged
with the duty of executing and issuing stock certificates to execute and issue the necessary certificates for the Conversion Shares upon the conversion of this Note. 

3.6        Issuance of New Note. Upon any partial conversion of this Note
and surrender of this Note, a new Secured Term A Note containing the same date and provisions of this Note shall be issued by the Company to the Holder for the unpaid Principal Amount and accrued and unpaid interest thereon which shall not have been
converted or paid. The Holder shall not pay any costs, fees or any other consideration to the Company for the production and issuance of a new Secured Term A Note. 

3.7        Rule 144 Limitations. Sales of the Conversion Shares by the
Holder will be subject to, and the Holder will comply with, the limitations on the number of shares of Biovest Common Stock that may be sold from time to time contained in Rule 144(e) of the Rules and Regulations under the Securities Act of 1933, as
amended, promulgated by the United States Securities and Exchange Commission (“Rule 144”), without regard to whether or not the Holder is considered an “Affiliate” of the Company for purposes of Rule 144(e). 

ARTICLE IV 

EVENTS OF DEFAULT 
 4.1        Events of Default. The occurrence of any Event of Default under the Security Agreement shall constitute an event of default (“Event of
Default”) hereunder. 
 4.2        Default Interest.
Following the occurrence and during the continuance of an Event of Default, the Company shall pay additional interest on the outstanding Principal Amount of this Note in an amount equal to the Contract Rate plus four percent (4%) per annum
(calculated based on a 365 day year), and all outstanding obligations under this Note, the Security Agreement and each other Ancillary Agreement, including unpaid interest, shall continue to accrue interest at such additional interest rate from the
date of such Event of Default until the date such Event of Default is cured or waived. 

4.3        Acceleration. Upon an Event of Default, the entire outstanding
Principal Amount, together with all accrued but unpaid interest and all amounts due and payable 

  
 6 

 
hereunder, shall be immediately due and payable hereunder, without notice or demand. Upon an Event of Default, Holder may exercise any and all other rights and remedies available to it under this
Note, the Security Agreement, the Guaranties, the other Ancillary Agreements and applicable law. 

4.4        Designated Directors. In addition to any other remedies
available to Holder under this Note, the other Ancillary Agreements or under applicable law, upon an Event of Default under Section 20(a) of the Security Agreement (after giving effect to any applicable grace period provided therein) (a
“Trigger Event”), the Agent shall be entitled in its sole discretion to appoint and maintain one-third (1/3) of the total number of directors of the Company (the “Designated Directors”) and to remove from
office any person so appointed and appoint another person in his or her stead or fill his or her vacancy if he or she shall resign. Following a Trigger Event, such right to appoint Designated Directors shall continue notwithstanding the
Company’s cure of any such Event of Default until the BVTI Term Notes have been paid in full. Upon the occurrence of a Trigger Event, the Board of Directors of the Company shall be restricted from taking any action until the Agent shall have
had a reasonable opportunity to appoint the Designated Directors, except that the Board of Directors of the Company shall, as promptly as practicable, take such action to permit compliance with the provisions of this Note, including, without
limitation, increasing the size of the Board of Directors to permit the Agent to appoint the Designated Directors and/or removal of existing directors. 
 ARTICLE V 
 MISCELLANEOUS 

5.1        Cumulative Remedies. The remedies under this Note shall be
cumulative. 
 5.2        Notice; Failure or Indulgence Not
Waiver. No failure or delay on the part of the Holder hereof in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude
other or further exercise thereof or of any other right, power or privilege. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available. The Company hereby waives all demands for
payment, presentations for payment, notices of intention to accelerate maturity, notices of acceleration of maturity, protest, notice of protest and notice of dishonor, to the extent permitted by law. 

Upon execution of this Note, the Company acknowledges, agrees and confirms that it has no defense, offset or counterclaim
for any occurrence in relation to this Note and the Company acknowledges that Holder has complied with all of its obligations under the Security Agreement as of the date hereof. The liability of the Company to the Holder shall be absolute and
unconditional and without regard to the liability of any other party. 

5.3        Notices. Any notice herein required or permitted to be given
shall be given in writing in accordance with the terms of the Security Agreement. 

5.4        Amendment Provision. The term “Note” and all
references thereto, as used throughout this instrument, shall mean this instrument as originally executed, or if later 

  
 7 

 
amended or supplemented, then as so amended or supplemented, and any successor instrument as such successor instrument may be amended or supplemented. This Note may not be amended or modified
without the written consent of the Holder and the Company, and subject, in any event, to the Security Agreement. 
 5.5        Assignability. This Note shall be binding upon the Company and its successors and assigns, and shall inure to the benefit of the Holder and its
successors and assigns, and may be assigned by the Holder in accordance with the requirements of Section 24 of the Security Agreement. The Company may not assign any of its obligations under this Note without the prior written consent of the
Holder and any such purported assignment without such consent shall be null and void. 

5.6        Cost of Collection. Following the occurrence of an Event of
Default under this Note, the Company shall, jointly and severally, pay the Holder the Holder’s reasonable costs of collection, including attorneys’ fees. 

5.7        Governing Law, Jurisdiction and Waiver of Jury Trial.

 (a)        THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED
IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW. 

(b)        THE COMPANY HEREBY CONSENTS AND AGREES THAT THE STATE AND/OR FEDERAL
COURTS LOCATED IN THE COUNTY OF NEW YORK, STATE OF NEW YORK SHALL HAVE EXCLUSIVE JURISDICTION TO HEAR AND DETERMINE ANY CLAIMS OR DISPUTES BETWEEN THE COMPANY, ON THE ONE HAND, AND THE HOLDER AND/OR ANY OTHER CREDIT PARTY, ON THE OTHER
HAND, PERTAINING TO THIS NOTE OR ANY OF THE OTHER ANCILLARY AGREEMENTS OR TO ANY MATTER ARISING OUT OF OR RELATED TO THIS NOTE OR ANY OF THE ANCILLARY AGREEMENTS; PROVIDED, THAT THE COMPANY ACKNOWLEDGES THAT ANY APPEALS FROM THOSE COURTS MAY
HAVE TO BE HEARD BY A COURT LOCATED OUTSIDE OF THE COUNTY OF NEW YORK, STATE OF NEW YORK; AND FURTHER PROVIDED, THAT NOTHING IN THIS NOTE SHALL BE DEEMED OR OPERATE TO PRECLUDE THE HOLDER AND/OR ANY OTHER CREDIT PARTY FROM BRINGING SUIT
OR TAKING OTHER LEGAL ACTION IN ANY OTHER JURISDICTION TO COLLECT THE OBLIGATIONS, TO REALIZE ON THE COLLATERAL OR ANY OTHER SECURITY FOR THE OBLIGATIONS, OR TO ENFORCE A JUDGMENT OR OTHER COURT ORDER IN FAVOR OF THE HOLDER AND/OR ANY OTHER CREDIT
PARTY. THE COMPANY EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND THE COMPANY HEREBY WAIVES ANY OBJECTION WHICH IT MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER
VENUE OR FORUM NON CONVENIENS. THE COMPANY AND THE HOLDER HEREBY WAIVE PERSONAL SERVICE OF THE SUMMONS, COMPLAINT AND OTHER PROCESS ISSUED IN ANY SUCH ACTION OR SUIT AND AGREE THAT SERVICE OF SUCH SUMMONS, COMPLAINT AND OTHER PROCESS MAY BE
MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO THE COMPANY, THE AGENT OR THE HOLDER, 

  
 8 

 
AS APPLICABLE, AT THE ADDRESS SET FORTH IN THE SECURITY AGREEMENT AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER OF THE COMPANY’S, THE AGENT’S OR THE HOLDER’S,
AS APPLICABLE, ACTUAL RECEIPT THEREOF OR THREE (3) DAYS AFTER DEPOSIT IN THE U.S. MAIL, PROPER POSTAGE PREPAID. 
 (c)        THE COMPANY DESIRES THAT ITS DISPUTES BE RESOLVED BY A JUDGE APPLYING SUCH APPLICABLE LAWS. THEREFORE, TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF
THE JUDICIAL SYSTEM AND/OR OF ARBITRATION, THE COMPANY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE, WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE BETWEEN THE HOLDER AND/OR ANY OTHER CREDIT
PARTY, ON THE ONE HAND, AND/OR THE COMPANY, ON THE OTHER HAND, ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION WITH THIS NOTE, ANY OTHER ANCILLARY AGREEMENT OR THE TRANSACTIONS RELATED
HERETO OR THERETO. 
 5.8        Severability. In the event that
any provision of this Note is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the limited extent that it may conflict therewith and shall be deemed modified to conform with
such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Note which shall be enforceable to the maximum extent permitted by
law. 
 5.9        Maximum Payments. Nothing contained herein
shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum
rate permitted by such law, any payments in excess of such maximum rate shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company. 

5.10        Security Interest. The Agent, for the ratable benefit of the
Credit Parties, has been granted a security interest in certain assets of the Company as more fully described in the Security Agreement and the other Ancillary Agreements. 

5.11        Construction; Counterparts. Each party acknowledges that its
legal counsel participated in the preparation of this Note and, therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation of this Note to favor any
party against the other. This Note may be executed by the parties hereto in one or more counterparts, each of which shall be deemed an original and all of which when taken together shall constitute one and the same instrument. Any signature
delivered by a party by facsimile or electronic transmission shall be deemed to be an original signature hereto. 

  
 9 

 5.12        Registered
Obligation. Notwithstanding any document, instrument or agreement relating to this Note to the contrary, transfer of this Note may only be effected in accordance with the Security Agreement. 

5.13        Only Registered Form of Notes. This Note is issued in
registered form only. The Company shall maintain a register which shall reflect the registration, transfer, conversion and exchanges of the Term A Notes. Any transfer, exchange or conversion of this Note is required to be registered on the register
of the Company and only upon surrender of this Note for registration, exchange, conversion or transfer at the office of the Company maintained for such purpose, or at such other location as designated by the Company, accompanied with such other
instruments as required by the Company, and thereupon one or more new Notes, of authorized denominations and for the same aggregate principal amount (or upon conversion, a reduced principal amount), will be issued to the Holder or designated
transferee or transferees. The Company shall treat the person in whose name this Note is registered in the register as the owner of this Note for the purposes of receiving payment of any amounts due hereunder and for all other purposes whatsoever in
connection with this Note. 
 IN WITNESS WHEREOF, the Company has caused this Secured Term A Note to be signed
in its name effective as of November 17, 2010. 
  

							
	WITNESS:	 		 	BIOVEST INTERNATIONAL, INC.
				
	 /s/ YiYi Lam
	 		 	By:	 	 /s/ David Moser

		 		 	Name:        David Moser
		 		 	Title:          Secretary

  
 10 

 EXHIBIT A 

NOTICE OF CONVERSION 
 (To be executed by the Holder in order to convert the 
 Secured Term A Note)

 The undersigned hereby elects to convert
$             of the principal and $             of the interest due on the Secured Term A Note dated as of
November 17, 2010 (the “Note”) issued by Biovest International, Inc. (the “Company”) into shares of Common Stock of the Company in accordance with the terms and conditions set forth in the Note, as of the date
written below. 
  

			
	Date of Conversion:	 	  

		
	Conversion Price:	 	  

		
	Shares to be Delivered:	 	  

		
	Signature:	 	  

		
	Print Name:	 	  

		
	Address:	 	  

		
	Holder DWAC instructions:	 	  

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]